This meeting was approved by the Federation of Royal Colleges of Physicians and the Royal Society of Biology.
2017 EVENTS & TRAINING

9 January 2017
OBESITY UPDATE
Royal College of Physicians
London

27 January 2017
NATIONAL CLINICAL CASES
Royal Society of Medicine
London
www.endocrinology.org/events/clinical-cases

20-21 March 2017
ENDOCRINE NURSE UPDATE
Hilton Birmingham
Metropole Hotel, NEC
Birmingham
www.endocrinology.org/events/endocrine-nurse-update

20-22 March 2017
CLINICAL UPDATE
Hilton Birmingham
Metropole Hotel, NEC
Birmingham
www.endocrinology.org/events/clinical-update

26-8 November 2017
SfE BES 2017
Harrogate International Centre, Harrogate

SfE PROGRAMME COMMITTEE
Simon Pearce (Newcastle upon Tyne)
Chair
Gareth Lavery (Birmingham)
Programme Co-ordinator
Robert Semple (Cambridge)
Programme Co-ordinator & Clinical Committee Programme Advisor
Ruth Andrew (Edinburgh)
Duncan Bassett (London)
Mandy Drake (Edinburgh)
Neil Gittoes (Edinburgh)
Kate Hardy (London)
Nils Krone (Birmingham)
Ann Logan (Birmingham)
Konstantinos Manolopoulos (Birmingham)
Early Career Endocrinologists Steering Group Representative
Amir Sam (London)
Lisa Shepherd (Birmingham)
Nurse Committee Chair
Helen Simpson (Cambridge)
Vicki Smith (Birmingham) Science Committee Programme Advisor
Welcome

We are delighted to provide you with the programme for the annual Society for Endocrinology BES conference 2016. We are sure that you will share our enthusiasm for the clinical and scientific content of the meeting.

This year’s meeting features 12 symposia covering a range of translational topics, starting at 10:30 on Monday. In addition, there will be basic science and clinical Meet the Expert sessions and clinical management workshops (including two “How do I manage?” sessions: back by popular demand) and, of course, the insightful poster presentations. Clinical case reports have always formed the core of the poster display at SfE BES, and for the first time we are pleased to bring you these as a searchable catalogue of ePosters. The most highly scoring of these Clinical Case reports will also be displayed as featured posters in the exhibition hall. Please take a little time to check-out the ePosters and do feedback how this new feature worked for you.

For PhD students and clinical trainees, we have specific workshops on practical publishing advice, the SCE exam, research funding and developing your endocrinology career. This exciting array of sessions will be crowned by 10 plenary lectures, where medal winners will present their research, including the Society for Endocrinology Jubilee Medal Lecture by Professor Sir Steve Bloom entitled ‘Gut & Money, customer shrunk’ which takes place 08:30 on Tuesday morning.

Other highlights include the Early Career Endocrinologists’ Prize Lectures, two Nurses’ sessions, a Senior Endocrinologists’ session and the annual debate, which this year features the topical issue of glucocorticoid replacement for adrenal insufficiency.

Remember to join us at the Welcome Reception on Monday evening in the exhibition hall, where drinks and music will provide the ideal setting to catch up with colleagues. Tuesday evening sees the annual conference dinner, in the newly commissioned British Airways i360. Don’t forget to book your place and join us for fabulous food and an evening of vibrant entertainment.

I’d also like to thank all of our exhibitors and sponsors. Please make the effort to visit their stands in the exhibition hall and attend their satellite sessions being held at lunchtime.

During the conference, please take time to explore Brighton. Apparently there’s the sea and some vibrant LGBT venues out there, but we guarantee these won’t be half as interesting as the endocrinology.

We welcome you to the Society for Endocrinology BES 2016 and look forward to the best of British and international basic science and translational research, clinical investigation and clinical practice in endocrinology.
**CORPORATE SUPPORTERS**

The Society for Endocrinology would like to thank its corporate supporters for their generous support.

<table>
<thead>
<tr>
<th>PARTNERSHIP LEVEL</th>
<th>Corporate Supporters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PLATINUM</strong></td>
<td>Pfizer</td>
</tr>
<tr>
<td><strong>GOLD</strong></td>
<td>bioscientifica</td>
</tr>
<tr>
<td><strong>SILVER</strong></td>
<td>Shire, Novartis, Merck Serono</td>
</tr>
<tr>
<td></td>
<td>Lilly, Ipsen</td>
</tr>
<tr>
<td></td>
<td>HRA Pharma</td>
</tr>
<tr>
<td></td>
<td>Strongbridge Biopharma</td>
</tr>
</tbody>
</table>

Corporate supporters are correct at the time of print.

**ACKNOWLEDGEMENTS**

**ABSTRACT MARKERS**

The Programme Committee wishes to thank the abstract markers for marking all of the submissions to this conference.

**SPONSORS & EXHIBITORS**

In addition to those listed previously, we are grateful to the following companies and organisations who have supported the Society for Endocrinology BES 2016 conference.

<table>
<thead>
<tr>
<th>ACC Support UK</th>
<th>Addison’s Disease Self Help Group</th>
<th>ALD Life</th>
<th>Alexion</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMEND</td>
<td>Besins Healthcare</td>
<td>British Thyroid Foundation</td>
<td>CAH Support Group</td>
</tr>
<tr>
<td>dsdfamilies</td>
<td>Ferring</td>
<td>Hypopara UK</td>
<td>Imaging Equipment Limited</td>
</tr>
<tr>
<td>International Society of Endocrinology</td>
<td>Internis</td>
<td>Klinefelter’s Syndrome Association</td>
<td>Kyowa Kirin Limited</td>
</tr>
<tr>
<td>Merck</td>
<td>Novartis Oncology/ Sandoz Biopharmaceuticals</td>
<td>Novo Nordisk</td>
<td>Pituitary Foundation</td>
</tr>
<tr>
<td>Strongbridge Biopharma</td>
<td>Turner Syndrome Support Society</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
WHAT TO EXPECT AT SFE BES 2016

This year’s SFE BES conference is set to be the best yet. We’ll be celebrating the Society for Endocrinology’s 70th anniversary, hosting initiatives to help you progress your professional career, and providing more opportunities than ever for scientists, clinicians and nurses to share the latest endocrine research, and discuss best practice in the field. Here’s what to look out for!

12 SYMPOSIA ... on cutting edge research and practice, such as novel approaches to endocrine neoplasia, advances in the genetic understanding of endocrine disease, and new frontiers for vitamin D.

10 PLENARY LECTURES ... including:
- Professor Sir Stephen Bloom’s Jubilee Medal Lecture: ‘Gut and money, customer shrunk’
- Professor Henry Kronenberg’s Transatlantic Medal Lecture: ‘Parathyroid hormone: builder and destroyer of bone’
- Professor Jason Carroll’s Society for Endocrinology Medal Lecture: ‘Understanding oestrogen receptor gene regulation in breast cancer’.

9 ‘MEET THE EXPERT’ SESSIONS ... exploring hot topics such as endocrine disruptors, the late endocrine effects of cancer treatment, and how to effectively treat endocrine patients in sport.

3 ‘FUTURES’ AND ‘SKILLS’ SESSIONS ... providing guidance on how to progress to the next stage in your endocrine career. This year you’ll be able to get tips on how to avoid common pitfalls in your grant proposals, how to maximise your chances in fellowship applications, and how to find out everything you need to know about the Specialty Certificate Exam.

2 LOUNGES ... for Nurses and Early Career Endocrinologists, providing space to network with colleagues.

1 DEBATE ... looking at the arguments for and against using prednisolone as the first line treatment for glucocorticoid replacement in adrenal insufficiency.

1 CONFERENCE DINNER ... an awards ceremony followed by a dinner to allow you to catch up with colleagues, old and new.

THE SOCIETY AND YOU

The Society for Endocrinology exists to bring the broad community of endocrinologists together – from basic and translational researchers through to clinical practitioners. The Society was founded 70 years ago with the goal of facilitating exchange of knowledge and ideas in our subject and this idea remains just as relevant today.

Our members are at the heart of everything we do. We are proud of our broad and diverse membership of researchers, clinicians, endocrine nurses, and students. You may be surprised to learn that we have members in over 60 countries and that 14% of our members are based outside of the UK. Our members have contributed to major advances in the understanding and treatment of endocrine disorders and have advanced the science that underpins endocrinology.

Our annual meeting of the SfE BES is the highlight of our year – last year’s conference was the most successful ever. We believe that it continues to play a crucial role in the information sharing that helps to advance our discipline. In addition to the formal programme, it is an opportunity to renew old acquaintances and forge some new friendships.

We would like to take this opportunity to thank our corporate supporters and exhibitors. They are a hugely important part of our community and their contribution helps to keep registration fees for the conference to a minimum. Please do visit the exhibition and talk to the exhibitors about the latest exciting developments emerging from industry.

We hope you enjoy the conference.
GRANTS, PRIZES AND AWARDS
Most of the society’s funds are distributed through grant schemes, which:
• help our members engage with the public through attending media training workshops to carry out public engagement activities
• support our members’ careers by helping them attend scientific conferences or visit other labs and clinics
• advance our members’ research by funding a number of schemes from undergraduate summer studentships to early career grants.

PUBLIC ENGAGEMENT
Our aim is for the public to have a better understanding of hormones and to make informed decisions about their health as a result. The Society proactively promotes discussion of endocrinology through the media and a programme of public events for adults, school children and families.
THE SOCIETY FOR ENDOCRINOLOGY ANNUAL GENERAL MEETING 2016

Be a part of...

THE SOCIETY AND YOU

OUR MEMBERS
Society members are part of the global endocrine community. By joining the Society for Endocrinology, you become part of a history of scientific and clinical excellence.

Being part of our community means you are kept at the forefront of developments in endocrinology and are able to benefit from the experiences of your peers, which in turn advances your own professional field.

Many of our members are world-leading endocrinologists; others are just starting out in the field. Regardless of your experience, you will be supported at every stage of your career and have the opportunity to be recognised for your contributions to the specialty.

Our members share the latest knowledge and best practice in endocrinology. In doing so, they expand their professional networks and build successful collaborations worldwide. We recognise that by collaborating within the specialty and the wider scientific community, we are in the strongest position to advance endocrinology.

JOIN US TODAY
For more information about becoming a member of the Society for Endocrinology, visit stand D60/D70 in the Exhibition Hall, Auditorium 1. See www.endocrinology.org/membership for further details or email members@endocrinology.org.

WIN A £25 AMAZON VOUCHER AT THE AGM THIS YEAR!

Simply complete the entry form found in your Monday lunch bag and hand it in at the AGM to be entered into the prize draw to win a £25 Amazon voucher.

Tuesday 8 November 2016
0 18.15 Auditorium 2

We look forward to seeing you there!
GENERAL INFORMATION

REGISTRATION
The registration desk will be open at the following times:
Monday 7 November 09:00–21:00
Tuesday 8 November 07:30–19:00
Wednesday 9 November 07:30–17:30

SECURITY
Please wear your badge at all times. Entrance will not be permitted to delegates who are not wearing badges. A cloakroom is available for your use. Bioscientifica Ltd, the Society for Endocrinology and the Brighton Centre cannot be held responsible for any belongings.

CATERING
Lunch is included in the cost of registration for Monday, Tuesday and Wednesday, and will be provided in the Exhibition Hall in Auditorium 1. Complimentary tea and coffee will be available on arrival and during scheduled breaks in the Exhibition Hall.

SPEAKERS
The slide preview facility will be located in Office 2, located on the 1st floor next to Auditorium 2, on the eastside. Please visit the speaker registration desk for more information.
Speaker Preview Room opening times:
Monday 7 November 09:00–19:00
Tuesday 8 November 07:30–18:30
Wednesday 9 November 07:30–17:00

POSTERS

ALL POSTERS
All posters will be on display in Auditorium 1 by 13:00 on Monday 7 November and will be available to view until 14:45 on Wednesday 9 November.

Early Career Endocrinologists’ posters will be judged on Monday 7 November and Tuesday 8 November during lunchtime.

ENDOCRINE NETWORK MEETINGS
Monday 7 November
Reproductive Endocrinology and Biology
10:45–11:45 Meeting Room 5
Thyroid
15:45–16:45 Meeting Room 5
Tuesday 8 November
Bone and Calcium
12:15–13:00 Meeting Room 5
Endocrine Neoplasia Syndromes
14:30–15:30 Meeting Room 5
Metabolic and Obesity
14:30–15:30 Meeting Room 3
Neuroendocrinology
16:30–17:30 Meeting Room 5
Wednesday 9 November
Adrenal and Cardiovascular
12:00–13:00 Meeting Room 5
Visit us at Stand D60/D70 to find out more and update your Endocrine Network preferences.

OTHER MEETINGS
Times and locations for other meetings arranged during the conference will be displayed on a notice board by the registration desk.

VENUE FACILITIES
Delegates at SFEBEs 2016 have access to free wifi, which will support normal browsing. Cloakrooms are available in the ground floor foyer and are free of charge. A multi-faith prayer room will also be available throughout the conference in Office 4 located on Level 2. Ask at the registration desk for more information.

EXHIBITION
Don’t miss your opportunity to network with your colleagues, reinvigorate existing collaborations or forge new links at the SFEBEs exhibition. The exhibition will be open in Auditorium 1 from Monday 7 November through to Wednesday 9 November.

- Discuss your latest research, abstracts or poster presentations
- Engage with exhibitors’ ongoing or prospective clinical trials
- Find out about available research support tools and grants
- Learn more about endocrine therapy management
- Enhance your networking opportunities

Our corporate supporters, educational programme sponsors and exhibitors are essential partners in the continuing work of the Society for Endocrinology. Their ongoing investment in Society events and services helps us achieve our goal to be a world-leading authority on hormones.

The exhibition closes at 15:00 on Wednesday. Delegates will not be allowed to access the Exhibition Hall after this time.
GENERAL INFORMATION

CPD APPROVAL
SfE BES 2016 has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 18 category 1 (external) CPD credits. The SfE BES 2016 conference has also been approved by the Royal Society of Biology. For purposes of CPD, this event may be counted as 96 credits.
SfE BES 2016 has been endorsed by the International Society of Endocrinology, as a meeting of high scientific and educational quality.

CERTIFICATE OF ATTENDANCE
Certificates of attendance will be available to print from Wednesday 9 November from the E-badge self-service stations in the registration area. Electronic certificates with CPD accreditation will be made available after the conference. A link to the online evaluation form will be emailed to you once the conference has finished. Once you have completed this form, a certificate of attendance, including CPD points, will be sent by email within 14 working days.

AWARDS

Society for Endocrinology

EARLY CAREER*
ENDOCRINOLOGISTS’ PRIZES
Prizes will be awarded to the two highest scoring oral communications in Oral Communications 1: Early Career on Monday 7 November at 15:30 in Auditorium 2.
In addition, there will be four highly commended prizes. All prizes will be presented during the Awards Ceremony on Wednesday 9 November at 16:45 in Auditorium 2.

*Early Career Endocrinologists are either up to 10 years postdoc or up until completion of clinical training (Scientist-in-Training and Clinician-in-Training Members, respectively)

Society for Endocrinology

SFE JUNIOR POSTER PRIZES
SfE BES 2016 will feature dedicated Junior Poster Prizes, designed specifically to showcase the up-and-coming talents of our Student Members.
Two highly commended certificates and one winner will be awarded for both Clinical and Basic Junior Posters. The certificates will be presented at the Awards Ceremony by the Chair of the Programme Committee.

AMEND

AMEND YOUNG INVESTIGATOR AWARD
This award is run by the Association for Multiple Endocrine Neoplasia Disorders (AMEND) in association with the Society for Endocrinology. The award is presented to the first author of the highest scoring abstract in the ‘Neoplasia, cancer and late effects’ category.
This year’s winner is Donato Iacovazzo (London) for ‘A missense mutation in the islet-enriched transcription factor MAFA leads to familial insulomatisos and diabetes’. This will be presented as OC1.5 in Oral Communications 1: Early Career session on Monday 7 November in Auditorium 2.

ANNETTE LOUISE SEAL AWARD
The Addison’s Disease Self-Help Group will present the Annute Louise Seal Memorial Award, with a prize of £500 for the nursing abstract which best advances the clinical management of steroid replacement therapy or adrenal insufficiency, where the first author is a nurse. Abstracts may cover any aspect of adrenal crisis prevention and treatment, the management and monitoring of steroid replacement therapy or associated patient education.
This year’s winner is Veronica Kieffer (Leicester) for ‘Steroid Replacement Education: Are We Getting It Right?’.
This year’s second place award winner is Deborah Papadopoulou (London) for ‘Prednisolone and fludrocortisone as once daily treatment following adrenalectomy’.

www.endocrinology.org/events
CLINICAL ENDOCRINOLOGY TRUST PRIZES
The Clinical Endocrinology Trust (CET) is an independent body that utilises profits from the publication of Clinical Endocrinology to support the development of endocrinology and the education of students and specialists.

The CET is pleased to support the following Plenary Lectures:

Clinical Endocrinology Trust Visiting Professor Lecture
The CET Visiting Professor Lecture will take place on Wednesday 9 November 2016 at 15:45 in Auditorium 2. The CET Visiting Professor, Martin Reincke (Munich, Germany) will present on Genomics and Steroidobolomics in Cushing’s syndrome: the perspective of a clinician scientist.

Clinical Endocrinology Trust Lecture
The CET Lecture will take place on Wednesday 9 November at 16:15 in Auditorium 2. The CET Lecturer, John Achermann (London), will present on Endocrine development is for life: looking beyond paediatrics.

The winners of the Clinical Endocrinology Trust prizes are as follows:

Top-scoring clinical abstract:
ORAL COMMUNICATIONS 3: Thyroid and Neoplasia
Tuesday 8 November 16:15–17:45
PRESENTING AUTHOR: Nadia Schoenmakers
TITLE: Frequent Occurrence of DUOX2 and DUOXA2 Mutations in Cases with Borderline Bloodspot Screening TSH who Develop ‘True’ Congenital Hypothyroidism

Top-scoring basic science abstract:
ORAL COMMUNICATIONS 1: Early Career
Monday 5 November 15:30–17:00
PRESENTING AUTHOR: Manu Verma
TITLE: 11β-HSD1 deficiency modulates brain energy homeostasis during acute systemic inflammation.

Top-scoring Nursing Practice abstract:
PRESENTING AUTHOR: Michael Tadman
TITLE: Somatostatin analogue tolerability testing in the management of Neuroendocrine Tumours (NETs), a single centre review of practice.

BRITISH THYROID ASSOCIATION AWARD
The British Thyroid Association is delighted to award this prize to a young researcher who has submitted a high quality abstract in the ‘Thyroid’ category.

This year’s winner is Alice Fletcher for ‘Identification of novel sodium iodide symporter (NIS) interactors which modulate iodide uptake’. This will be presented as OC3.4 in Oral Communications 3: Thyroid and Neoplasia on Tuesday 8 November in Syndicate 1.

AWARDS

EARLY CAREER ENDOCRINOLOGISTS’ PRIZE LECTURES
The winners of the SFEndo Prize Lectures will give their presentations on Tuesday 8 November from 09:00 in Auditorium 2.

Basic Science Prize winner:
Eleanor Raffan (Cambridge) will present ‘Woofing it down – lessons on the neurobiology of appetite from man’s best friend’

Clinical Prize winner:
Tim Korevaar (The Netherlands) will present ‘Interpretation of gestational thyroid function measurements: Clinical risks and physiological considerations’

Clinical Cases Poster Prize
• This prize is provided by the Society for Endocrinology in association with Endocrinology, Diabetes & Metabolism Case Reports. The winner will be awarded £200 and will be entitled to publish their case for free in the open-access resource EDM Case Reports, which publishes insightful case reports in all areas of clinical endocrinology, diabetes and metabolism (standard publication charge £350).
• The top 10 featured clinical cases will be under review at the meeting to determine a winning poster.
• The winning case report will be subject to peer review, therefore ultimate publication cannot be guaranteed.

SOCIETY FOR ENDOCRINOLOGY JOURNAL AWARDS
The Society for Endocrinology Annual Journal Awards will be presented to the authors of papers of the highest standard published in Journal of Endocrinology, Journal of Molecular Endocrinology, Endocrine-Related Cancer, Clinical Endocrinology and Endocrine Connections.

Selection was made by the journal editorial boards followed by ratification by the Chair of the Publications Committee. One award has been made per journal. The awards recognise excellence in endocrinology research and practice, and their contribution to the wider biomedical and biological sciences field. There is an enormous amount to celebrate with outstanding work being carried out internationally. The papers we publish are testament to the quality, dedication and innovation in service to endocrinology.

A nominated author from each group will receive their certificate at the Conference Dinner.

GET THE LATEST INFORMATION...
WELCOME RECEPTION
Monday 7 November 2016
19:15, Exhibition Hall, Auditorium 1
Join your fellow delegates for drinks and snacks in the Exhibition Hall at the The Brighton Centre. This is a great introduction to the conference, and opportunity to engage with the corporate supporters.

EARLY CAREER* DINNER AND QUIZ
Monday 7 November 2016
19:45, The Restaurant, The Brighton Centre, Third Floor
Join your fellow Early Career Endocrinologists* for an evening of fun, drinks and dinner. Tickets are free to Early Career Endocrinologists but must be booked in advance as there is limited availability. Please inform us if you select this at the time of registration, but no longer plan to attend this free activity.

If you have not arrived by 20:00 your space could be given to those on the waiting list.

CONFERENCE DINNER AND AWARDS CEREMONY
Tuesday 8 November 2016
19:30, British Airways i360
Join fellow delegates for this year’s Conference Dinner at Brighton’s newest attraction, the British Airways i360. This provides a great opportunity to relax and dine with your friends and colleagues. Awards will be presented to the Society for Endocrinology Dale medallist, Jubilee medallist and journal award winners (note all other awards will be presented after their talk).

Please ensure you arrive promptly at 19:30 and the pre-dinner drinks will include a trip up the viewing tower. Delegates must make their own way to British Airways i360, which is a four minute walk from The Brighton Centre.

Tickets £60.00 (Early Career Endocrinologists* and Concessionaries £40.00). Tickets must be booked in advance. Please ask at registration desk for availability

Please ensure you have advised us of any dietary requirements prior to the evening.

*Early Career Endocrinologists are either up to 10 years postdoc or up until completion of clinical training (Scientist-in-Training and Clinician-in-Training Members, respectively).
Get involved online at SfE BES 2016!

Whether it’s Twitter, Facebook or other forms of social media, we want you to stay up-to-date, discuss the latest conference news and make the most of virtual networking this year. You can find our social media policy on page 87.

www.twitter.com/Soc_Endo

www.facebook.com/societyforendocrinology

INFORMATION ON THE GO

Maximise your time at SfE BES 2016 with the SfE BES 2016 mobile website, giving you fast and simple access to sessions, speakers, abstracts, exhibitors, networking, social media and more! The mobile website is completely free and is available for Apple, Android and Blackberry devices. Accessing the mobile website is easy!

HOW TO GET THE MOBILE WEBSITE ON YOUR DEVICE

**STEP 1: QR CODE**

Do you have a barcode scanner on your device? Simply scan this QR code to be directed straight to the mobile website. A barcode scanner can easily be downloaded from your app-store.

**WEB SEARCH**

Type the following link
http://sfebes2016.endocrinology.org into your device’s browser. The link will automatically direct you to the mobile website.

**STEP 2:**

On your mobile device bookmark the URL and add a shortcut on your home screen. You will now be able to use the web application offline.

**MONDAY 7 NOVEMBER**

Scientific programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–21:00</td>
<td>Registration</td>
</tr>
</tbody>
</table>

**Symposium 1**

10:30–12:00
SYNDICATE 1

10:30
S1.1
How to manage patients with acromegaly and discordant GH and IGF-I results
Peter Trainer (Manchester)

11:00
S1.2
Protons and the Pituitary: Who to treat and how it works
Ed Smith (Manchester)

11:30
S1.3
Quality of life in patients with pituitary disease
Niki Karavitaki (Birmingham)

**Symposium 2**

10:30–12:00
SYNDICATE 3

10:30
S2.1
Designer drugs: uncoupling the beneficial and harmful effects of glucocorticoids
Karolien DeBosscher (Ghent, Belgium)

11:00
S2.2
Combination therapies that lighten the glucocorticoid load
Rob Newton (Calgary, Canada)

11:30
S2.3
Effective delivery of anti-inflammatory glucocorticoids is a matter of timing
Julie Gibbs (Manchester)

**Symposium 3**

10:30–12:00
AUDITORIUM 2

10:30
S3.1
The new bone biology
Duncan Bassett (London)

11:00
S3.2
Inhibiting cathepsin K
Bente Langdahl (Aarhus, Denmark)

11:30
S3.3
Targeting Wnt signalling in osteoporosis
Socrates Papapoulos (Leiden, the Netherlands)

**CHALLENGES IN PITUITARY DISEASE**

Chairs: Claire Higham (Manchester) & Craig Parkinson (Ipswich)

**GRAPPLING WITH THE FUTURE OF ANTI-INFLAMMATORY STEROIDS**

Next generation therapeutic strategies to improve the risk/benefit ratio of glucocorticoid drugs in inflammatory disease
Chairs: Mark Nixon (Edinburgh) & David Ray (Manchester)

**OSTEOPOROSIS: TRANSLATING THE NEW BONE BIOLOGY**

The science of osteoporosis treatment
Chairs: Fadid Hannan (Liverpool) & Henry Kronenberg (Cambridge, USA)

Supported by Journal of Endocrinology and Turner Syndrome Support Society (UK)

**GET INVOLVED**

Introduction

Society for Endocrinology BES 2016
MONDAY 7 NOVEMBER
Scientific programme

Practical Publishing Advice Workshop
10:30–12:00
SYNDICATE 4
10:30
PPAW1.1
Introduction
Maralyn Druce (London)

10:35
PPAW1.2
The art of scientific writing
Maralyn Druce (London)

10:50
PPAW1.3
The peer review process and responding to reviewer comments
Colin Farquharson (Edinburgh)

11:05
PPAW1.4
Publishing ethics – fabrication, falsification and plagiarism
Chris McCabe (Birmingham)

11:20
PPAW1.5
How to increase the impact of your article
Victoria Merriman (Bristol)

11:35
PPAW1.6
Question & answer session

Futures 1
12:15–13:00
SYNDICATE 4
12:15
FUT1.1
What has endocrinology done for me?
Karim Meeran (London)

12:25
FUT1.2
Endocrine careers: a trainee’s view
Christine May (Birmingham)

12:35
FUT1.3
Why, where and when to do endocrinology research
Stephen O’Rahilly (Cambridge)

Skills 1
12:15–13:00
SYNDICATE 1
12:15
SK1.1
SCE ENDOCRINOLOGY: EVERYTHING YOU WANTED TO KNOW BUT WERE AFRAID TO ASK
Chairs: Konstantinos Manolopoulos (Birmingham) & Marie Freil (Glasgow)

SCE endocrinology: everything you wanted to know but were afraid to ask
Mark Gurnell (Cambridge)

Meet the Expert 1
12:15–13:00
SYNDICATE 3
12:15
MTE1
EXTRACELLULAR VESICLES IN HEALTH AND DISEASE
Novel signalling mechanisms
Chair: Charlotte Lawson (London)
Supported by Clinical Endocrinology

12:15
MTE2
SOCIETY FOR ENDOCRINOLOGY GUIDANCE ON THE LATE ENDOCRINE EFFECTS OF CANCER TREATMENT
Meet the Expert 2
12:15–13:00
AUDITORIUM 2
Supported by Clinical Endocrinology

12:15
MTE2
Society for Endocrinology guidance on the late endocrine effects of cancer treatment
Helen Simpson (Cambridge)

13:00–14:15
LUNCH & POSTER VIEWING
EXHIBITION HALL, AUDITORIUM 1

13:15–14:15
INDUSTRY-SPONSORED SATELLITE SYMPOSIA
(full details can be found on page 70)

Plenary Lecture 1
14:15–14:45
AUDITORIUM 2
Chair: Karen Chapman (Edinburgh)

14:15
PL1
Understanding oestrogen receptor gene regulation in breast cancer
Jason Carroll (Cambridge)

Plenary Lecture 2
14:45–15:15
AUDITORIUM 2
Chair: Simon Pearce (Newcastle upon Tyne)

14:45
PL2
From Genetic and Genomic to the patient
Mercedes Robledo (Madrid, Spain)

Symposium 4
15:30–17:00
SYNDICATE 1
15:30
S4.1
New insights in molecular genetics of congenital adrenal hyperplasia
Nils Krone (Sheffield)

16:00
S4.2
Applying new developments in the genetic understanding of inherited pituitary adenoma
Albert Beckers (Liège, Belgium)

16:30
S4.3
Somatic mutations and remodelling in hyperaldosteronism
Morris Brown (Cambridge)
## Monday 7 November
### Scientific Programme

### Symposium 5

**Symposium 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>OCT1.5</td>
<td>NEW FRONTIERS FOR VITAMIN D</td>
<td>Ivan Hernandez (Birmingham) &amp; Claire Wood (London)</td>
</tr>
<tr>
<td>15:30</td>
<td>OCT1.6</td>
<td>A missense mutation in the islet-enriched transcription factor MAFA leads to familial insulinomatosis and diabetes</td>
<td>Donato Iacovazzo (London)</td>
</tr>
<tr>
<td>15:45</td>
<td>OCT1.7</td>
<td>A time controlled β-cell specific mouse model MenIL/L/RIP2-CreER for pancreatic neuroendocrine tumours (NETs)</td>
<td>Roeland P Vas Nunes (Oxford)</td>
</tr>
</tbody>
</table>

### Symposium 6

**Symposium 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>OCT3.1</td>
<td>WHY ENDOCRINOLOGISTS SHOULD PAY ATTENTION TO GUT FEELINGS</td>
<td>Kevin Murphy (London) &amp; Mariana Norton (London)</td>
</tr>
<tr>
<td>15:30</td>
<td>OCT3.2</td>
<td>The vicious cycle of immune dysregulation and obesity</td>
<td>Donal O’Shea (Dublin, Ireland)</td>
</tr>
<tr>
<td>15:30</td>
<td>OCT3.3</td>
<td>New links between the gut endocrine system and the nervous system</td>
<td>Diego Bohorquez (Durham, USA)</td>
</tr>
<tr>
<td>15:30</td>
<td>OCT3.4</td>
<td>Metabolic surgery: how to choose the correct bariatric surgical option</td>
<td>Francesco Rubino (London)</td>
</tr>
</tbody>
</table>

### Oral Communications 1

**Oral Communications 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>OCT1.1</td>
<td>Mutations in SGPL1, encoding sphingosine-1-phosphate lyase, cause a novel form of primary adrenal insufficiency with steroid resistant nephrotic syndrome</td>
<td>Rathi Prasad (London)</td>
</tr>
<tr>
<td>15:45</td>
<td>OCT1.2</td>
<td>11β-HSD1 deficiency modulates brain energy homeostasis during acute systemic inflammation</td>
<td>Manu Verma (Edinburgh)</td>
</tr>
<tr>
<td>15:45</td>
<td>OCT1.3</td>
<td>Investigating the interaction between KNDy peptides on gonadotrophin release in humans – novel findings with therapeutic importance</td>
<td>Shakunthala Narayanaswamy (London)</td>
</tr>
<tr>
<td>16:15</td>
<td>OCT1.4</td>
<td>The urinary steroid metabolome as a non-invasive tool to stage non-alcoholic fatty liver disease</td>
<td>Ahmad Moolla (Oxford)</td>
</tr>
</tbody>
</table>

### Oral Early Career Communications 1

**Oral Early Career Communications 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>OCT1.5</td>
<td>‘Free vitamin D’: another twist in the vitamin D story?</td>
<td>Martin Hewison (Birmingham)</td>
</tr>
<tr>
<td>15:30</td>
<td>OCT1.6</td>
<td>Vitamin D and brain development</td>
<td>Daryl Eyles (Brisbane, Australia)</td>
</tr>
<tr>
<td>15:30</td>
<td>OCT1.7</td>
<td>Prevention and management of nutritional rickets: a 21st century approach</td>
<td>Wolfgang Högl (Birmingham)</td>
</tr>
</tbody>
</table>
TUESDAY 8 NOVEMBER
Scientific programme

07:30-19:00
REGISTRATION

Plenary Lecture 5
08:30-09:00
AUDITORIUM 2
08:30
PL5

SOCIETY FOR ENDOCRINOLOGY
JUBILEE MEDAL LECTURE
Chair: Barbara McGowan (London)
Gut & money, customer shrunk
Steve Bloom (London)

Prize Lectures
09:00-10:00
AUDITORIUM 2
09:00
ECP1.1
09:30
ECP1.2

EARLY CAREER ENDOCRINOLOGISTS’ PRIZE LECTURES
The Society awards two prizes to Early Career Endocrinologists,
one basic science and one clinical
Chairs: Barbara McGowan (London) & Karen Chapman (Edinburgh)

09:00
Basic Science: Woofing it down – lessons on the neurobiology of appetite from man’s best friend
Eleanor Raffan (Cambridge)

09:30
Clinical: Interpretation of gestational thyroid function measurements:
clinical risks and physiological considerations
Tim Korevaar (Rotterdam, The Netherlands)

10:00–10:30
TEA & COFFEE
EXHIBITION HALL, AUDITORIUM 1

Symposium 7
10:30-12:00
SYNDICATE 1

HORMONES THROUGH THE AGES
Hormonal changes from childhood to old age
Chairs: Kim Jonas (London) & Paul Newey (Dundee)

10:30
S7.1
11:00
S7.2
11:30
S7.3

Testosterone and the HPG axis in the ageing male
Fred Wu (Manchester)

Thyroid and ageing
Diana Van Heemst (Leiden, The Netherlands)

Glucocorticoids and the ageing brain
Joyce Yau (Edinburgh)

Clinical Management Workshop 1
10:30-12:00
AUDITORIUM 2

ENDOCRINOLOGY AT THE EDGE OF THE REFERENCE RANGE
Chairs: Paul Newey (Dundee) & Antonia Brooke (Exeter)
Supported by Endocrinology, Diabetes & Metabolism Case Reports and Clinical Endocrinology

10:30
CMW1.1
11:00
CMW1.2
11:30
CMW1.3

Normocalcaemic hyperparathyroidism – treat or discharge?
Graham Leese (Dundee)

Low testosterone and normal gonadotrophins. Who, when and how to treat?
Richard Quinton (Newcastle upon Tyne)

Mild glucocorticoid autonomy and the adrenal nodule:
medical or surgical management?
John Newell-Price (Sheffield)
TUESDAY 8 NOVEMBER
Scientific programme

Early Career Symposium
10:30–12:00
SYNDICATE 3

LAUNCHING YOUR CAREER, WHATEVER IT MAY BE
Chairs: Nyo Nyo Tun (Edinburgh) & Craig Doig (Birmingham)

Opportunities for developing your transferrable skills with the Society for Endocrinology
Chris McCabe (Birmingham)

10:45
EC1.2

A career in professions allied to science and medicine
Victoria Cabrera-Sharp (Oxford)

11:00
EC1.3

How to combine an academic career as an NHS clinician
Barbara McGowan (London)

11:15
EC1.4

The route to floristry via medicine
Anna Mitchell (Newcastle upon Tyne)

11:30
EC1.5

Rejection from Tesco – how to make your PhD work
Samantha Mirczuk (London)

Nurse Session 1
10:30–12:00
SYNDICATE 4

PREPARING FOR ENDOCRINE PREGNANCIES
Pre-conception to post-delivery care
Chair: Nikki Kieffer (Leicester) & Frances Kay (Brighton)

10:30
N1.1

Congenital Adrenal Hyperplasia
Eleni Daniel (Sheffield)

11:00
N1.2

Thyroid
Kristien Boelaert (Birmingham)

11:30
N1.3

Prolactinoma
Aled Rees (Cardiff)

Meet the Expert 3
12:00–12:45
SYNDICATE 1

SPORT – HOW TO SUPPORT ENDOCRINE PATIENTS IN SPORT: FROM RECREATION TO OLYMPICS
Chair: Nishan Guha (Oxford)

Supported by Clinical Endocrinology

12:00
MTE3

Sport – how to support endocrine patients in sport: from recreation to Olympics
Rob Andrews (Bristol)

Meet the Expert 4
12:00–12:45
SYNDICATE 3

REAL-TIME METABOLOMICS IN CLINICAL SETTINGS
Chair: Ruth Andrew (Edinburgh)

Supported by Clinical Endocrinology

12:00
MTE4

I-Knife® technology – in vivo diagnostics
Zsolt Bodai (London)

Meet the Expert 5
12:00–12:45
AUDITORIUM 2

NUTRITIONAL SUPPORT POST BARIATRIC SURGERY
Nutritional support post bariatric surgery
Barbara McGowan (London)

Futures 2
12:00–12:45
SYNDICATE 4

MAPPING YOUR ROUTE THROUGH THE RESEARCH FUNDING MAZE
Chair: Wiebke Arlt (Birmingham)

12:00
FUT2.1

Starter grants and building your pilot data
Roland Stimson (Edinburgh)

12:15
FUT2.2

A view from the funding body: avoiding pitfalls in grant applications
Helen Thompson (London)

12:30
FUT2.3

Maximising your chances in fellowship applications; Writing and interviewing
Brian Walker (Edinburgh)

12:45–14:15
LUNCH & POSTER VIEWING
EXHIBITION HALL, AUDITORIUM 1

13:00–14:00
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM
(full details can be found on page 71)

Symposium 8
14:15–15:45
SYNDICATE 3

THYROID HORMONE: THE JOURNEY FROM CELL SURFACE TO ACTION
Chairs: Graham Williams (London) & Vicki Smith (Birmingham)

Supported by Journal of Molecular Endocrinology

14:15
S8.1

Thyroid hormone transport into target tissues
Heike Heuer (Düsseldorf, Germany)

14:45
S8.2

Thyroid hormone metabolism in target tissues
Monica Dentice (Napoli, Italy)

15:15
S8.3

Thyroid hormone receptor localisation in target tissues
Lizabeth Allison (Williamsburg, USA)
TUESDAY 8 NOVEMBER
Scientific programme

Clinical Management Workshop 2
14:15–15:45
AUDITORIUM 2

ADRENAL INSUFFICIENCY AND CONGENITAL ADRENAL HYPERPLASIA (CAH)

Chairs: Katherina Lang (Birmingham) & Brian Walker (Edinburgh)
Supported by ALD Life, Addison’s Disease Self Help Group and Clinical Endocrinology
14:15
CMW2.1
Dynamic control of tissue glucocorticoids and its implications for replacement therapy
Brian Walker (Edinburgh)
14:45
CMW2.2
Adrenal crisis and outcome of Addison’s disease
Stephanie Hahner (Wurtzberg, Germany)
15:15
CMW2.3
Outcome in CAH around the globe
Miguel De Bono (Sheffield)

Nurse Session 2
14:15–15:45
SYNDICATE 4

MALE FERTILITY
Paediatric to adult
Chairs: Sofia Llahana (London) & Lisa Shepherd (Birmingham)
Supported by The Klinefelter’s Syndrome Association
14:15
N2.1
Male puberty and spermatic development
Kate Davies (London)
14:45
N2.2
Primary infertility
Elizabeth Williamson (London)
15:15
N2.3
Secondary infertility
Andrew Dwyer (Lausanne, Switzerland)

Oral Communications 2
14:15–15:45
SYNDICATE 1

NEUROENDOCRINOLOGY AND REPRODUCTION
Six oral communications from selected abstracts submitted by delegates
Chairs: Stephen Franks (London) & Steve Hillier (Edinburgh)
14:15
OC2.1
Kisspeptin, a neuroendocrine modulator of sexual and emotional processing in men
Alexander Comninos (London)
14:30
OC2.2
MLE4901, a neurokinin 3 receptor antagonist, shows reproductive tract effects and sustained pharmacodynamic activity consistent with HPG suppression after 13 weeks of oral administration in dogs
Stephen Hunt III (Ann Arbor, USA)
14:45
OC2.3
Associations between karyotype and long term health outcomes in adults with Turner Syndrome; The Turner Syndrome Life Course Project
Antoinette Cameron-Pimblett (London)
15:00
OC2.4
Heteromers of luteinising hormone and follicle stimulating hormone receptor positively and selectively modulates the LH-induced calcium signalling response
Kim Jonas (London)

TUESDAY 8 NOVEMBER
Scientific programme

15:15
OC2.5
Ipilimumab Hypophysitis - single centre experience of an emerging endocrine diagnosis
Lai Zhuangming Marc (London)
15:30
OC2.6
Dysregulation of the steroidogenic gene network in granulosa cells from women with PCOS
A Lerner (London)

15:45–16:15
TEA & COFFEE

EXHIBITION HALL, AUDITORIUM 1

Symposium 9
16:15–17:45
SYNDICATE 4

EXPOSING THE SINS OF OUR FATHERS (AND MOTHERS)
Early life programming of disease risk: mechanisms and consequences
Chairs: Steve Franks (London) & Andrew Childs (London)
16:15
S9.1
Maternal nutrition, epigenetics and foetal development
Tom Flemming (Southampton)
16:45
S9.2
Epigenetic mechanisms in the transgenerational transmission of disease risk – myth or reality?
Amanda Drake (Edinburgh)
17:15
S9.3
Life course influences on health: evidence from human studies
Robin Beaumont (Exeter)

Clinical Management Workshop 3
16:15–17:45
AUDITORIUM 2

HOW DO I …
Chairs: Marie Freel (Glasgow) & Christine May (Birmingham)
Supported by Endocrinology, Diabetes & Metabolism Case Reports and Clinical Endocrinology
16:15
CMW3.1
How do I approach drug-induced hyperprolactinaemia?
Paul Newey (Dundee)
16:30
CMW3.2
How do I rule out insulinoma?
Helen Simpson (Cambridge)
16:45
CMW3.3
How do I titrate testosterone therapy?
Pierre Bouloux (London)
17:00
CMW3.4
How do I manage refractory hypercalcaemia?
Jeremy Turner (Norwich)
17:15
CMW3.5
How do I prepare a patient for phaeo surgery?
Amir Sam (London)
17:30
CMW3.6
How do I determine cortisol deficiency in the critically ill patient?
Jeremy Tomlinson (Oxford)
### Oral Communications 3

**16:15 OC3.1**

Frequent occurrence of DUOX2 and DUOXA2 mutations in cases with borderline bloodspot screening TSH who develop 'true' congenital hypothyroidism

Nadia Schoenmakers (Cambridge)

**16:30 OC3.2**

Pharmacological enhancement of radiiodine uptake through Src kinase inhibition

Vicki Smith (Birmingham)

**16:45 OC3.3**

Post-radioiodine Graves’ management: The Pragma-Study

Petros Perros (Newcastle upon Tyne)

**17:00 OC3.4**

Identification of novel sodium iodide symporter (NIS) interactors which modulate iodide uptake

Vasileios Chortis (Birmingham)

**17:15 OC3.5**

Identification of murine neuroendocrine tumour (NET) cell binding peptides identified through phage display

Alice Fletcher (Birmingham)

**17:30 OC3.6**

Oestrogens Stimulate Proliferation in Colorectal Cancer via GPER and the Hippo signalling pathway

Mark Stevenson (Oxford)

### Oral Communications 4

**16:15 OC4.1**

Novel brain biomarkers of cognitive abnormalities identified in patients with congenital adrenal hyperplasia

Emma A Webb (Birmingham)

**16:30 OC4.2**

Nicotinamide riboside and cellular NAD+ redox state influence 11β-HSD1 mediated glucocorticoid regeneration in skeletal muscle cells

Yasir Elhassan (Birmingham)

**16:45 OC4.3**

Genome wide ChIP-Seq analysis of Glucocorticoid Receptor and RNA Polymerase 2 binding in rat liver during physiological and non-physiological corticosterone replacement.

Benjamin P. Flynn (Bristol)

**17:00 OC4.4**

A Single Nucleotide Polymorphism in the BACH2 Gene Contributes to Susceptibility to Autoimmune Addison’s Disease in UK and Norwegian cohorts

Agnieszka Pazderska (Newcastle upon Tyne)
### Scientific Programme

**Symposium 10**

**Symposium 10 CLINICAL THYROIDOLOGY UPDATE**

**Plenary Lecture 7**

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td><strong>Parathyroid hormone: builder and destroyer of bone</strong></td>
<td>Henry Kronenberg (Boston, USA)</td>
</tr>
<tr>
<td>09:45</td>
<td><strong>Thyroid incidentalomas: US, CT, MR and PET</strong></td>
<td>Petros Perros (Newcastle upon Tyne)</td>
</tr>
<tr>
<td>10:15</td>
<td><strong>Thyroiditis: post-partum, subacute and new drugs</strong></td>
<td>Mark Vanderpump (London)</td>
</tr>
<tr>
<td>10:45</td>
<td><strong>Sick euthyroid syndrome</strong></td>
<td>Anita Boelen (Amsterdam, The Netherlands)</td>
</tr>
</tbody>
</table>

**Symposium 11**

**Symposium 11 DIABETES MELLITUS – IT’S ALL ABOUT THE BETA CELL, STUPID!**

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45</td>
<td><strong>Islet beta-cell failure in type 2 diabetes</strong></td>
<td>Neil Hanley (Manchester) &amp; Ali Chakera (Brighton)</td>
</tr>
<tr>
<td>10:15</td>
<td><strong>Beta-cell adaptation and failure during progression of type 2 diabetes</strong></td>
<td>Ross Laybutt (Sydney, Australia)</td>
</tr>
<tr>
<td>10:45</td>
<td><strong>The role of mitochondrial metabolism in the control of insulin secretion</strong></td>
<td>Hindrik Mulder (Lund, Sweden)</td>
</tr>
</tbody>
</table>
**Scientific programme**

**SENIOR ENDOCRINOLOGISTS’ SESSION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45</td>
<td>SE1.1</td>
<td>Geoff Gill (Liverpool)</td>
<td>Difficult hyponatraemia – does the ‘sick cell syndrome’ exist?</td>
<td>Paul Belchetz (Leeds) &amp; Ian Mason (Edinburgh)</td>
</tr>
<tr>
<td>10:05</td>
<td>SE1.2</td>
<td>Alan McNeilly (Edinburgh)</td>
<td>Conservation endocrinology – what, are there more than two species to consider?</td>
<td>Alan McNeilly (Edinburgh)</td>
</tr>
<tr>
<td>10:45</td>
<td>SE1.4</td>
<td>Steve Hillier (Edinburgh)</td>
<td>On gonads and gadflies: the oestrus angle</td>
<td></td>
</tr>
</tbody>
</table>

**Applied Physiology Workshop 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45</td>
<td>APW1.1</td>
<td>Lorna Kennedy (Manchester)</td>
<td>Unravelling endocrine autoimmunity in companion animals</td>
<td>Lorna Kennedy (Manchester)</td>
</tr>
<tr>
<td>10:15</td>
<td>APW1.2</td>
<td>Laurent Sachs (Paris, France)</td>
<td>Developmental actions of thyroid hormone: an amphibian approach</td>
<td>Laurent Sachs (Paris, France)</td>
</tr>
<tr>
<td>10:45</td>
<td>APW1.3</td>
<td>Deborah Kurrasch (Calgary, Canada)</td>
<td>Employing zebrafish to study neuroendocrine programming</td>
<td>Deborah Kurrasch (Calgary, Canada)</td>
</tr>
</tbody>
</table>

**Symposium 12**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45</td>
<td>S12.1</td>
<td>Paul Newey (Dundee)</td>
<td>Identification of new therapeutic targets in MEN1</td>
<td>Paul Newey (Dundee)</td>
</tr>
<tr>
<td>12:15</td>
<td>S12.2</td>
<td>Olympia Kououri (Cambridge)</td>
<td>Novel techniques for nuclide imaging in pituitary and adrenal tumours</td>
<td>Olympia Kououri (Cambridge)</td>
</tr>
<tr>
<td>12:45</td>
<td>S12.3</td>
<td>Kate Newbold (London)</td>
<td>Clinical advances in thyroid cancer treatment</td>
<td>Kate Newbold (London)</td>
</tr>
</tbody>
</table>

**Clinical Management Workshop 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>CMW4.2</td>
<td>Steve Franks (London)</td>
<td>How should I counsel a young woman with PCOS about fertility?</td>
<td>Steve Franks (London)</td>
</tr>
<tr>
<td>12:15</td>
<td>CMW4.3</td>
<td>James Ahlquist (Southend)</td>
<td>How long should I treat prolactinoma?</td>
<td>James Ahlquist (Southend)</td>
</tr>
<tr>
<td>12:30</td>
<td>CMW4.4</td>
<td>Andy Toogood (Birmingham)</td>
<td>How do I manage florid Cushing’s syndrome?</td>
<td>Andy Toogood (Birmingham)</td>
</tr>
<tr>
<td>12:45</td>
<td>CMW4.5</td>
<td>Anna Crown (Brighton)</td>
<td>How do I manage hypothalamic amenorrhoea?</td>
<td>Anna Crown (Brighton)</td>
</tr>
<tr>
<td>13:00</td>
<td>CMW4.6</td>
<td>Sue Jackson (Bristol)</td>
<td>How do I detect depression in the endocrine clinic?</td>
<td>Sue Jackson (Bristol)</td>
</tr>
</tbody>
</table>

**Oral Communications 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45</td>
<td>OC5.1</td>
<td>Christopher Sainsbury (Glasgow)</td>
<td>Does type of diabetes, and treatment prescribed prior to admission influence quality of treatment of inpaitent hypoglycaemia?</td>
<td>Christopher Sainsbury (Glasgow)</td>
</tr>
<tr>
<td>12:00</td>
<td>OC5.2</td>
<td>Rachel Jennings (Manchester)</td>
<td>Glucagon-like peptide-1 secretion within the developing human fetus and its role in beta cell development</td>
<td>Rachel Jennings (Manchester)</td>
</tr>
<tr>
<td>12:15</td>
<td>OC5.3</td>
<td>Hernan Fainberg (Nottingham)</td>
<td>Depot specific transcriptional signatures of adipose tissue in sheep and humans during early life</td>
<td>Hernan Fainberg (Nottingham)</td>
</tr>
<tr>
<td>12:30</td>
<td>OC5.4</td>
<td>Myuri Moorthy (London)</td>
<td>Two contrasting cases of spontaneous severe hypoglycaemia secondary to anti-insulin antibodies (Insulin Autoimmune Syndrome / Hirata disease)</td>
<td>Myuri Moorthy (London)</td>
</tr>
<tr>
<td>12:45</td>
<td>OC5.5</td>
<td>Nikolaos Nikolau (Oxford)</td>
<td>5α-reductase (AKR1D1) is a potent regulator of carbohydrate and lipid metabolism in human and rodent liver</td>
<td>Nikolaos Nikolau (Oxford)</td>
</tr>
<tr>
<td>13:00</td>
<td>OC5.6</td>
<td>Samantha Laber (Oxford)</td>
<td>IRX3 regulates Adipocyte Browning via Mitochondrial Complex 1 Genes</td>
<td>Samantha Laber (Oxford)</td>
</tr>
</tbody>
</table>
WEDNESDAY 9 NOVEMBER
Scientific programme

Meet the Expert 8: THE ADOLESCENT WITH DSD
14:45–15:30
SYNDICATE 1
Supported by dsdfamilies and Clinical Endocrinology
The adolescent with DSD
Faisal Ahmed (Glasgow)

Meet the Expert 9: ILLUMINATING THE ISLETS
14:45–15:30
SYNDICATE 4
Supported by Clinical Endocrinology
Using photo-pharmacology to reveal the importance of the islet beta cell network
David Hodson (Birmingham)

Plenary Lecture 9
15:45–16:15
AUDITORIUM 2
Chair: Weibke Arlt (Birmingham)
Genomics and steroidobolomics in Cushing’s syndrome: the perspective of a clinician scientist
Martin Reincke (Munich, Germany)

Plenary Lecture 10
16:15–16:45
AUDITORIUM 2
Chair: Barbara McGowan (London)
Endocrine development is for life: looking beyond paediatrics
John Achermann (London)

AWARDS CEREMONY
16:45–17:00
AUDITORIUM 2

CLOSING REMARKS
17:00-17:15
AUDITORIUM 2
Monday 7 November
• Reproductive Endocrinology and Biology
  16:45 - 11:45  Meeting Room 5
• Thyroid
  16:45 - 16:45  Meeting Room 5

Tuesday 8 November
• Bone and Calcium
  12:15 - 13:00  Meeting Room 5
• Endocrine Neoplasia Syndromes
  14:30 - 15:30  Meeting Room 5
• Metabolic and Obesity
  Tuesday 14:30 - 15:30  Meeting Room 3
• Neuroendocrinology
  16:30 - 17:30  Meeting Room 5

Wednesday 9 November
• Adrenal and Cardiovascular
  12:00 - 13:00  Meeting Room 5

Posters

All posters will be on display in Auditorium 1 at the Brighton Centre by 13:00 on Monday 7 November and will be available to view until 14:45 on Wednesday 9 November.

POSTERS AND EPOSTERS
ATTENDED POSTER VIEWING
• Odd-numbered posters will be attended on Monday 7 November at 13:00-14:15.
• Even-numbered posters will be attended on Tuesday 8 November at 13:00-14:15.
• Nominated posters will be attended at the poster viewing sessions on both Monday 7 and Tuesday 8 November at 13:00-14:15.

Please note: Prize nominees are asked to attend both poster viewing sessions to allow all members of the judging panel to visit the nominated posters and interact with the poster authors. All prizes will be announced at the Awards Ceremony on Wednesday 9 November at 16:45-17:00, in Auditorium 2.

The SfE BES 2016 abstracts will be available to view approximately 2 weeks before the meeting on the meeting website, which can be accessed at: www.endocrinology.org/meetings/2016/sfebess2016abstracts.aspx.

POSTERS
During this year’s conference there will be a selection of clinical cases presented in an electronic poster (ePoster) format. These clinical cases ePosters cover a range of topics within the field of endocrinology and will be available on the ePoster stations found throughout the Exhibition Hall.

We hope that this new format will ensure that the exposure to these clinical cases is extended past the end of the SfE BES 2016 conference. ePosters will be available to view throughout the meeting, and after the conference on the Endocrine Abstracts portal.

Where available, posters can be viewed online at www.endocrine-abstracts.org

EARLY CAREER ENDOCRINOLOGISTS’ POSTERS
The 30 highest scoring posters submitted by Early Career Endocrinologists will be judged during the attended poster viewing times only. Presenters of the 10 highest scoring posters (basic science and clinical) will be asked to attend their posters during the lunch break on Wednesday 9 November, in Auditorium 1, for the final judging and evaluation.

Of the 10 highest selected, two winning posters (one clinical and one basic science) will be given a prize of £500.

*Early Career Endocrinologists are either up to 10 years postdoc or up until completion of clinical training (Scientist-in-Training and Clinician-in-Training Members, respectively).

FEATURED CLINICAL CASES
10 ‘featured clinical cases’ have been selected by the Programme Committee to be highlighted in this year’s distinguished poster display. These posters cover topical issues spanning the breadth of endocrinology. The featured posters (CCI-CC10) can be found in the distinctive poster board area in Auditorium 1.

DISPLAYING YOUR POSTER
Posters must be displayed by 13:00 on Monday 7 November. Auditorium 1 can be accessed to display posters from 09:00 on Monday 7 November. All posters MUST be removed by 15:00 on Wednesday 9 November. There will be no access to the auditorium after this time and any remaining posters will be disposed of.
**POSTERS**

**POSTER KEY**

- P1 - P41 ADRENAL
- P42 - P61 BONE & CALCIUM
- P62 - P89 CLINICAL BIOCHEMISTRY
- P90 - P119 DIABETES
- P120 - P137 NEOPLASIA, CANCER AND LATE EFFECTS
- P138 - P171 NEUROENDOCRINOLOGY & PITUITARY
- P172 - P173 NURSING
- P174 - P199 OBESITY

**FEATURED CLINICAL CASES**

**CC1** Life-threatening cardiac arrhythmias following treatment of newly diagnosed Addison’s disease
J Rochester, E D Aflorei, A Roberts, A Wilton

**CC2** More than just diabetes insipidus
Xilin Wu, Alan Choo-Kang

**CC3** Tremelimumab-induced Graves’ disease
Earn H Gan, Ruth Plummer, Simon Pearce, Petros Perros

**CC4** Asymptomatic elevated PTH level due to immunoassay interference resulting from Macro-PTH: a case report
Paul Prodan, Eka Nandoshvili, Craig Webster, Jayadave Shakher

**CC5** A case report of a symptomatic osteopoikilosis patient caused by novel mutation in LEMD3
Khaled Tofeeq, Handrean Soran, Zulf Mughal, Per Selby

**CC6** Vitamin D-dependent rickets type I caused by a novel frameshift mutation of the 25-hydroxyvitamin D-α-hydroxylase gene (CYP27B1)
Victoria Stokes, Caroline Gorvin, Brian Shine, Rajesh Thakker

**CC7** Spurious diagnosis of phaeochromocytoma due to drug-induced symptoms and abnormal investigation results
R Preece, J Rochester, E D Aflorei, A Wilton

**CC8** Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): two unusual cases of cyclical ectopic adrenocorticotropic hormone secretion
Sarah N Ali, Maura Moriarty, Lisa Yang, Jonathan Anderson, Jeannie F Todd

**CC9** Successful treatment of primary aldosteronism with partial adrenalectomy, facilitated by the use of 11C-metomidate PET/CT
Wael Bashari, Andrew Powlson, Olympia Koulouri, Denis Quill, Morris Brown, Heok Cheow, Michael Conall Denney, Mark Gurnell

**CC10** ACTH-dependent Cushing’s syndrome unmasked following transphenoidal surgery for acromegaly – the rare coexistence of dual endocrinopathies
Parizad Avari, Aditi Sharma, Quirinius Barnor, Thomas Galliford, Arla Ogilvie, Chantal Kong
Adrenal vein sampling for subtype
P15 Adrenal vein sampling for subtype
classification of primary aldosteronism
in British Columbia: insights and
classification of primary aldosteronism
in British Columbia: insights and challenges
Pol Darras & Daniel Holmes

P16 Comparison of insulin tolerance test
P23 The pharmacokinetic profile
performance with other dynamic tests
of cortisol reserve
Payal Maria, Tricia Tan & Emma Hatfield
of cortisol reserve

P17 The effect of time of day and utility of
P24 Tissue-specific regulation of recycling
30- and 60-minute values in 250 mcg
between cortisol and cortisone by
ACTH stimulation test
Vicki Munro, Manal Elhenein, Steve
insulin and obesity
Douscette, Stephanie Kaiser & Syed Ali
of insulin and obesity
Imran

P18 Primary adrenal insufficiency -
P25 Random spot urinary metanephrines
establishing aetiology and screening for
correlated to 24-H collection in the
correlated to 24-H collection in the
determining autoimmunity of Cushing's
determining autoimmunity of Cushing's
diagnosis and follow-up of
syndrome
ATR-101, a selective ACAT1
pseudocortical and paragangliomas: preliminary
antagonist, in dogs
treatment trials in dogs
results

P19 Adrenal crisis - an important endocrine
emergency needing ongoing education
P26 Could modified release prednisone hold
P27 Structural analysis of nicotinamide
P28 Incidence and outcomes of hormone-
deepening adrenal crises in Cushing's
nucleotide transhydrogenase (NHT)
secretory adrenal tumours in pregnancy:
genetic variants causing adrenal
diseases in a tertiary clinic
that key to closer reproduction of the
diseases in a tertiary clinic
adrenal insufficiency?
Pui San Yap, Maria Gemma Rodriguez
Cushing's
carrier
Pui San Yap, Maria Gemma Rodriguez
Cushing's
carrier
Carnero, Asha Harshaghatta, Alison Milne,
Carnero, Asha Harshaghatta, Alison Milne,
Alex Graveling, Sam Philip & Prakash
Alex Graveling, Sam Philip & Prakash
Abraham
Abraham

P20 A quality improvement project to refine
diagnostic testing for adrenal
P29 Oestrogen excess induces instability and
P30 What does patient understand about how
to self-manage acute adrenal
loss of arterial identity in the forming
loss of arterial identity in the forming
deficiency?
insufficiency?
insufficiency?

P21 Diagnosis of adrenal sufficiency using a
highly specific cortisol immunoassay:
major implications for clinicians
P29 Cushing's
P30 What does patient understand about how
to self-manage acute adrenal
Krause
Krause

P22 What does patient understand about how
to self-manage acute adrenal
P31 Cushing’s syndrome - a
diagnostic test:
insufficiency?
insufficiency?
insufficiency?

P23 The pharmacokinetic profile
P32 Failed adrenal crisis management
of prednisolone is not affected by
P33 Could modified release prednisone hold
ingestion of food - how should
Could modified release prednisone hold
patients be advised?
patients be advised?

P24 Tissue-specific regulation of recycling
between cortisol and cortisone by
insulin and obesity

P25 Random spot urinary metanephrines
correlated to 24-H collection in the
determining autoimmunity of Cushing's
treatment trials in dogs

P26 Could modified release prednisone hold
the key to closer reproduction of the
defeehting adrenal crisis in Cushing's
diseases in a tertiary clinic
adrenal insufficiency?
Pui San Yap, Maria Gemma Rodriguez
Cushing’s
carrier
Carnero, Asha Harshaghatta, Alison Milne,
Carnero, Asha Harshaghatta, Alison Milne,
Alex Graveling, Sam Philip & Prakash
Alex Graveling, Sam Philip & Prakash
Abraham
Abraham
Biotin deficiency vs 60-min cortisol during SST
Biotin deficiency vs 60-min cortisol during SST
Pui San Yap, Maria Gemma Rodriguez
Carnero, Asha Harshaghatta, Alison Milne,
Alex Graveling, Sam Philip & Prakash
Abraham
Abraham

P20 A quality improvement project to refine
diagnostic testing for adrenal
deficiency?
insufficiency?
insufficiency?

P21 Diagnosis of adrenal sufficiency using a
highly specific cortisol immunoassay:
major implications for clinicians
Krause
Krause

P22 What does patient understand about how
to self-manage acute adrenal
deficiency?
insufficiency?
insufficiency?

P23 The pharmacokinetic profile
P32 Failed adrenal crisis management
of prednisolone is not affected by
ingestion of food - how should
patients be advised?

P24 Tissue-specific regulation of recycling
between cortisol and cortisone by
insulin and obesity

P25 Random spot urinary metanephrines
correlated to 24-H collection in the
determining autoimmunity of Cushing's
treatment trials in dogs

P26 Could modified release prednisone hold
the key to closer reproduction of the
defeehting adrenal crisis in Cushing's
diseases in a tertiary clinic
adrenal insufficiency?
Pui San Yap, Maria Gemma Rodriguez
Cushing’s
carrier
Carnero, Asha Harshaghatta, Alison Milne,
Carnero, Asha Harshaghatta, Alison Milne,
Alex Graveling, Sam Philip & Prakash
Alex Graveling, Sam Philip & Prakash
Abraham
Abraham

P21 Diagnosis of adrenal sufficiency using a
highly specific cortisol immunoassay:
major implications for clinicians
Krause
Krause

P22 What does patient understand about how
to self-manage acute adrenal
deficiency?
insufficiency?
insufficiency?

P23 The pharmacokinetic profile
P32 Failed adrenal crisis management
of prednisolone is not affected by
ingestion of food - how should
patients be advised?
Suppression of 11β-hydroxysteroid dehydrogenase type 1 target gene regulation by hypoxia
Bushra Shammout, Adewonuola Alase, Miriam Wittmann, Paul Stewart & Ana Tiganescu

Maternal smoking disrupts adrenal steroid production in the human foetus
Zoe Johnston, Michelle Bellingham, Denise Hough, Panagiotis Filis, Peter O’Shaughnessy & Paul Fowler

Discovery of putative aldosterone-regulating microRNAs by analysis of in vitro and in vivo microRNA profiles
Nur Izah Ab Razak, Scott MacKenzie, Stacy Robertson, Martin McBride, Marie Freel & Eleanor Davies

What is the most appropriate cut-off for post-saline aldosterone in saline suppression test after adrenalectomy?
Ruvini Ranasinghe, David Taylor, Benjamin Whitelaw, Simon Aylwin & Rocey Vincent

The human foetal adrenal proteome: Suppression of 11β-hydroxysteroid dehydrogenase type 1 mediates anti-inflammatory, pro-inflammatory and inflammation-independent effects in primary human dermal fibroblasts
Adewonuola Alase, Ian Carr, Paul Stewart & Ana Tiganescu

The role of 9am cortisol level to predict response to short synacthen test in hypoadrenalism
Najaf Haider, Pankaj Verlekar & Ma’en Al-Mrayat

Development and evaluation of the acceptability of new materials to address individualised needs to support self-management for patients with adrenal insufficiency
S Llahana, J Webber, S Chapman, PV Carroll, P McBride, D Phillips & R Horne

IONISED CALCIUM FROM BLOOD GAS

Impact of primary hyperparathyroidism and its treatment on bone mineral density, bone mineral parameters, insulin resistance, body composition and quality of life – a prospective pilot study from India
Thomas V Paul, Shinath Shetty, Nitin Kapoor, Sahana Shetty, M J Paul, Deepak Abraham, Pooja Ramakant, Joseph Dian & Nihal Thomas

The influence of gender on the bone health of adolescent patients with hormonal deficiencies
Pauline Whittingham, Kerrie Grounds, Aftab Ahmad, Mo Didi & Pamela Corlett

The calcitropic SHRP35 rectifies hypocalcaemia and reduced parathyroid hormone concentrations in a mouse model for autosomal dominant hypocalcaemia type 1 (ADHI)
Fadil Hannan, Valerie Babinsky, Caroline Gorvin, Teriis Hough, Elizabeth Joyson, Michelle Stewart, Sara Wells, Roger Cox, Edward Nemeth & Rajesh Thakker

Immunomodulation by vitamin D is associated with regulation of microRNAs
Danyang Li, Louisa E. Jeffery, Karim Raza & Martin Hewison

Ionised calcium from blood gas measurements, often overlooked
Sushuma Kaldindhi, Bonnie Dhas, Ananth Nayak & Biju Jose

Studies of an autosomal dominant hypocalcaemia type-1 (ADHI)-associated calcium-sensing receptor (CaSR) mutation, Arg680Gly, provides insights into biased signalling
Caroline Gorvin, Valerie Babinsky, Anders Schou, Peter Nissen, Fadil Hannan, Valerie Babinsky, Caroline Gorvin, Teriis Hough, Elizabeth Joyson, Michelle Stewart, Sara Wells, Roger Cox, Edward Nemeth & Rajesh Thakker

Emergency management of hypercalcaemia (an audit of SfE guidance in Oxford)
Haval Surchi & Paul Grant

The impact of primary hyperparathyroidism – an audit
Sameer Sighakoli & Trevor Wheatley

Continuous synthetic PTH1-34 replacement therapy in the treatment of autosomal dominant hypoparathyroidism type 1
Vidhya Jahaigirdar, Heather Stirling & Saisiah Sankar

Importance of bone mineral density care in transitional endocrine service
Karunya Yogesanwar & Aftab Ahmad

Diagnostic and surgical approaches bridging the gap between clinician and scientist through computational approaches
Elizabeth Baranowski, Kerstin Bunte, Cedric Shackleton, Angela Taylor, Beverley Hughes, Michael Bielih, Peter Tino, Tulya Gurain & Wibke Arnt

Effect of month of birth on the risk of development of autoimmune Addison’s disease
Agnieszka Paderszka, Marta Fichna, Anna Mitchell, Catherine Napier, Eam Gan, Marek Ruchala, Mauro Santibanez-Koref & Simon Pearce

The mechanistic role of fibroblast growth factor 21 (FGF21) in growth hormone resistance secondary to chronic childhood conditions
Jayna Narendra Mistry, Gerard Ruiz-Babot, Leonardo Guasti & Leo Dunkel
An audit of success rates of the
www.endocrinology.org/events
Gonadotropin induction of spermatogenesis clinic at University College London Hospitals
Anastasia Dimakopoulou, Taofeeq Ojewuyo, Sofia Llahana, Stephanie Baldeweg & Gerard Conway

The effects of Vitamin D on the outcomes of controlled ovarian stimulation in women with and without polycystic ovary syndrome undergoing in vitro fertilisation
Thomas Cunningham, Victoria Allgar, Stephen Atkin, Eric Kilpatrick, Stephen Maguiness & Thozhukat Sathyapalan

Bacterial isolates associated with semen and mouth of infertile men
Titilola Samuel, Obomobike Olagunju & Segun Nkwator

Anti-Müllerian hormone (AMH) and antral follicle count (AFC) are predictive markers in the assessment of patients with menstrual disturbance
Ali Abbara, Sophie Clarke, Rachel Roberts, Sunita Vimaleswaran, Alexander Comininos, Georgios Christophoulou, Rumana Islam, Steven Franks, Geoffrey Trew & Waldjit Dhillon

Profiling the decidualisation response of women with endometriosis reveals diverse patterns of steroid responsiveness
Ioannis Simitsidellis, Douglas A Gibson, Olympia Keleopati, Andrew W Horne & Philippa T K Saunders

Safety and tolerability of inducing completion of puberty with IM testosterone over 1 year in older men with congenital hypogonadism and absent puberty
Aggiezka Pazderska, Satish Artham, Margaret Miller, Margaret Morris, Steve Ball & Richard Quinton

Insight into the molecular mechanisms underlying alterations in gonadotropin receptor activity in polycystic ovary syndrome
Lisa Owens, Avi Lerner, Silvia Sposini, George Christophoulou, Shiran Khanjani, Razia Islam, Stuart Lavery, Vicky Tsui, Kate Hardy, Stephen Franks & Aylin Hanyaloglu

13:00–14:15 during lunch time

Insight into the molecular mechanisms underlying alterations in gonadotropin receptor activity in polycystic ovary syndrome
Lisa Owens, Avi Lerner, Silvia Sposini, George Christophoulou, Shiran Khanjani, Razia Islam, Stuart Lavery, Vicky Tsui, Kate Hardy, Stephen Franks & Aylin Hanyaloglu

The relation of liver enzymes and insulin resistance in women with polycystic ovary syndrome (PCOS)
Djuro Macut, Ivana Bozic-Antic, Konstantinos Tzimalos, Jelica Bjelek-Macut, Dusan Ilic, Danijela Vojnovic-Milutinovic,Olivera Stanojlovic & Dimitrios Panidis

Correlation of maternal serum insulin growth factor 1 and 2 to predict foetal outcome
Amit Gupta, Swasti Tiwari & Nisha Singh

Fertility effects of curcumin - a kitchen spice on male Wistar rat Balarine Iranloye & Oghochukwu Uweru

Androsterone Glucuronide to dehydroepiandrosterone sulphate ratio is higher in obese Caucasian women with polycystic ovary syndrome
Thozhukat Sathyapalan, Lina Ahmed, Brian Keevil, Adrian Miller, Eric Kilpatrick & Stephen Atkin

A prospective cohort study investigating endocrine disrupting agents and polycystic ovary syndrome within an IVF setting
Thomas Cunningham, Victoria Allgar, Stephen Atkin, Eric Kilpatrick, Stephen Maguiness & Thozhukat Sathyapalan

DNA-seq of mouse arcuate nuclei reveals pathways perturbed by glucocorticoid treatment
Jonathan Wray, Erika Harno, Alison Davies, Charlotte Sefton, Tiffany-Jayne Allen, Brian Y H Lam, Giles H Yeo & Anne White

Impact of weight gain on long-term outcomes in women with Turner syndrome: the Turner syndrome life course project
Antoinette Pimbblet, Thomas J King, Vikram Talaulikar, Melanie Davies & Gerard Conway

L-Phenylalanine modulates gut hormone release, and suppresses food intake in streptozotocin-induced diabetic mice
Vinod Joseph, Manish Kushe, Suresha Muniyappa & Chinnador Rajeswaran

Understanding and supporting pregnancy in ex vivo adipose tissue explant culture
Bashair Al Riyami, Simon Langley-Evans, Andrew Saltar & Jumana Saleh

Adminstration of FGF21 analogue ameliorates hyperglycaemia in streptozotocin-induced diabetic mice
In-Kyu Lee

Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with PCOS
Thozhukat Sathyapalan, Zeeshan Javed, Eric S Kilpatrick, Anne-Marie Coady & Stephen L Atkin

ALTERATIONS OF SPECIFIC CAVEOLIN ISOFORMS REVEALED BY THE EFFECTS OF VITAMIN D ON THE OUTCOMES OF CONTROLLED OVARIAN STIMULATION IN WOMEN WITH AND WITHOUT POLYCYSTIC OVARY SYNDROME (PCOS)

L-Phenylalanine modulates gut hormone release, and suppresses food intake in streptozotocin-induced diabetic mice.

Insight into the molecular mechanisms underlying alterations in gonadotropin receptor activity in polycystic ovary syndrome.

DNA-seq of mouse arcuate nuclei reveals pathways perturbed by glucocorticoid treatment.

Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is higher in obese Caucasian women with polycystic ovary syndrome.

A prospective cohort study investigating endocrine disrupting agents and polycystic ovary syndrome within an IVF setting.

The relation of liver enzymes and insulin resistance in women with polycystic ovary syndrome (PCOS).

Fertility effects of curcumin - a kitchen spice on male Wistar rat.

Androsterone Glucuronide to dehydroepiandrosterone sulphate ratio is higher in obese Caucasian women with polycystic ovary syndrome.
Levels of reactive oxygen species (ROS) in the seminal plasma predicts the effectiveness of L-carnitine to improve sperm function in men with infertility
Wayne Vessey, Cassandra McDonald, Ashraf Virmani, P Almeida, Channa Jayasekara & Jonathan Ramsay

Five-year follow-up of patients who received radioiodine therapy at district general hospital
Hussam Abusahmin

Optimising the medical treatment of Graves’ disease through developing a novel carbimazole-dosing algorithm
Rosalind Brewster, Ali Abbara, Sophie Clarke, Alexander Commins, Deborah Peters, Amir Sam, Karim Meeran & Waljit Dhill

Epidemiology, management and outcomes of Graves’ disease in a UK population – a retrospective cohort study
Yusuf Hussain, Jessica Hookham, Amizah Badabadi & Sapapphire Balasubramanian

Contrasting phenotypes in resistance to thyroid hormone α correlate with divergent properties of thyroid hormone receptor β1 mutant proteins
Carla Moran, Maura Agostini, Anne McGowan, Erik Schoenmakers, Louise Fairall, Greta Lyons, Odelia Rajanayagam, Laura Watson, Amaka Offiah, John Barton, Susan Price, John Schwabe & Krishna Chatterjee

Five-year follow-up of patients who received radioiodine therapy at district general hospital
Hussam Abusahmin

Optimising the medical treatment of Graves’ disease through developing a novel carbimazole-dosing algorithm
Rosalind Brewster, Ali Abbara, Sophie Clarke, Alexander Commins, Deborah Peters, Amir Sam, Karim Meeran & Waljit Dhill

Epidemiology, management and outcomes of Graves’ disease in a UK population – a retrospective cohort study
Yusuf Hussain, Jessica Hookham, Amizah Badabadi & Sapapphire Balasubramanian

Contrasting phenotypes in resistance to thyroid hormone α correlate with divergent properties of thyroid hormone receptor β1 mutant proteins
Carla Moran, Maura Agostini, Anne McGowan, Erik Schoenmakers, Louise Fairall, Greta Lyons, Odelia Rajanayagam, Laura Watson, Amaka Offiah, John Barton, Susan Price, John Schwabe & Krishna Chatterjee

Five-year follow-up of patients who received radioiodine therapy at district general hospital
Hussam Abusahmin

Optimising the medical treatment of Graves’ disease through developing a novel carbimazole-dosing algorithm
Rosalind Brewster, Ali Abbara, Sophie Clarke, Alexander Commins, Deborah Peters, Amir Sam, Karim Meeran & Waljit Dhill

Epidemiology, management and outcomes of Graves’ disease in a UK population – a retrospective cohort study
Yusuf Hussain, Jessica Hookham, Amizah Badabadi & Sapapphire Balasubramanian

Contrasting phenotypes in resistance to thyroid hormone α correlate with divergent properties of thyroid hormone receptor β1 mutant proteins
Carla Moran, Maura Agostini, Anne McGowan, Erik Schoenmakers, Louise Fairall, Greta Lyons, Odelia Rajanayagam, Laura Watson, Amaka Offiah, John Barton, Susan Price, John Schwabe & Krishna Chatterjee
<table>
<thead>
<tr>
<th>Posters</th>
<th>Posters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P245</strong> Thyroid autoantibody as a biomarker of breast cancer outcome: large-scale study using data from the Taxotere as Adjutant Chemotherapy Trial (TACT: CRUK01/001) Ilaria Muller, Priy Kiblum, Peter Taylor, Peter Barrett-Lee, Judith Bliss, Ellis Paul, Ludgate Marian &amp; Colin Dayan</td>
<td><strong>P251</strong> Distribution of free T4 levels in patients with low-risk thyroid cancer on thyroid hormone replacement and pituitary diseases: comparison with the normal population Kyhatisha Sejabe, Nikolaos Kyriakakis, Georgina Garrard, Vanessa Gill &amp; Robert D Murray</td>
</tr>
<tr>
<td><strong>P246</strong> High tumour expression of PBF and PTTG modulates the DNA damage response and is associated with poor survival in thyroid cancer Martin Read, Jinn Fang, Waraporn Imruetaiaorachenoke, Hannah Nieto, Bhatika Modasia, Alice Fletcher, Rebecca Thompson, Neil Sharma, Andrea Bacon, John Watson, Kristien Boelaert, Andrew Turnell, Vicki Smith &amp; Christopher McCabe</td>
<td><strong>P252</strong> Weight-related concerns in endocrine outpatients and its relationship to thyroid function Angelos Kyriacou, Alexis Kyriacou &amp; Nicholas Economides</td>
</tr>
<tr>
<td><strong>P247</strong> Aiming for a serum TSH in the higher reference range in older levothyroxine-treated hypothyroid individuals - a randomised controlled proof of concept trial (SORTED 1) Salman Razvi</td>
<td><strong>P253</strong> Prognostic factors of unsuccessful medical treatment of hyperthyroidism; longitudinal analysis of outcomes in the cohort of 538 patients Barbara Torlinska, Oliver Johnson &amp; Kristien Boelaert</td>
</tr>
<tr>
<td><strong>P248</strong> One-third of thyroid radionuclide uptake scans is deferentially interpreted leading to potentially differential treatment for patients with thyrotoxicosis Aftab Aziz, Tamar Avides, Richard Poyner, Bijay Vaidya &amp; Kashyap Patel</td>
<td><strong>P254</strong> An audit on fixed dose (555 MBq) radioactive-iodine for hyperthyroidism at a university hospital Arun Muthukurupan Alagar Vijay, Julie Cooper, Lakshminarayanan Varadhan &amp; Ananth U Nayak</td>
</tr>
<tr>
<td><strong>P249</strong> ESR2 mutations in RET mutation-negative familial medullary thyroid carcinoma Wazir K Afghan, Donato Iacovazzo, Maria Alevizaki, William Foukes, Francesca Lugli, Marlyn Druce, Pinaki Dutta, Mary N Dang, Plamena Gabrovskia, Patrick J Morrison, Martina Owens, Shan Ellard, Julian Sampson, Laura De Marinis &amp; Márta Korbonits</td>
<td><strong>P255</strong> Comparison of post-operative histology versus pre-operative cytology in thyroidectomy patients who had two pre-operative fine needle aspirates (FNA) Gurmint Gill, Sushma Kailindri, Paul Wilson, Kirthik Kalysundaram, George Varugheese &amp; Lakshminarayanan Varadhan</td>
</tr>
<tr>
<td><strong>P250</strong> Auditing outcomes post radioiodine therapy in patients with hyperthyroidism Venugopal Viral, Vito Carone, Thrasos Macriyiannis &amp; Miles Levy</td>
<td><strong>P256</strong> How effective are thyroid ultrasound and cytology compared with histology in identifying thyroid malignancy in thyroidec tomy patients? Sushma Kailindri, Gurmint Gill, George Varugheese &amp; Lakshminarayanan Varadhan</td>
</tr>
<tr>
<td><strong>P257</strong> Vitamin D supplementation in Graves’ disease and risk of relapse Suhel Ashraft, Caroline Addison, Vasileios Tsatslids &amp; Salman Razvi</td>
<td><strong>EP258</strong> The fluctuating clinical and biochemical thyroid status of patients with oscillating TSH receptor antibody predominance Georgina Wordsworth, Lia Angelouva &amp; Tony Robinson</td>
</tr>
<tr>
<td><strong>P258</strong> The fluctuating clinical and biochemical thyroid status of patients with oscillating TSH receptor antibody predominance Georgina Wordsworth, Lia Angelouva &amp; Tony Robinson</td>
<td><strong>EP8</strong> Will the routine use of high dose steroids for alcoholic hepatitis result in an increased incidence of clinically significant hypocortisolism in patients with liver cirrhosis? Priya Karia, Vassilis Bravis, Victoria Salem, Shiva Radhakrishnan &amp; Dri Choa</td>
</tr>
<tr>
<td><strong>EP9</strong> Case of prolonged hypoadrenocorticism after unilateral adrenalectomy for Conn’s syndrome Natasha Shinkhrina, Naing Koko, Ellen Jones, Betty Loumpardia, Steven Wong &amp; Aye Nyunt</td>
<td><strong>EP10</strong> Psediatric Cushing’s syndrome due to primary pigmented nodular adrenocortical disease Dia Eddine Boudiaf &amp; Farida Chentli</td>
</tr>
<tr>
<td><strong>EP11</strong> Elevated renin levels heralds adrenocortical involvement in a case of adrenoeculeodystrophy Mehjaeen Beejeebana, Laura To, Yaqza Hussain, Matthew Craner, Frances Coyle, Emma Bingham &amp; Jennifer Tringham</td>
<td><strong>EP12</strong> Bilateral adrenal haemorrhage secondary to non-meningococcal sepsis Malgorzata Lubczynski, Thrasos Macriyiannis &amp; Marie-France Kong</td>
</tr>
<tr>
<td><strong>EP13</strong> Phaeochromocytoma in pregnancy Kavitha Dhevi Krishnasamy Ganapathy, Murali Ganguri, Shilpa Mahadasu &amp; Rasha Mukhtar</td>
<td><strong>EP14</strong> “Not another bloody case of low sodium” Sobia Arshad &amp; Denis Barnes</td>
</tr>
<tr>
<td><strong>EP15</strong> Primary pigmented nodular adrenocortical disease: a rare cause of Cushing’s syndrome Catriona Kyle &amp; Roland Stimson</td>
<td><strong>EP16</strong> X-linked adrenoleukodystrophy – a rare cause of Addison’s disease Claudia Matta-Coelho, Selma B Souto &amp; Olinda Marques</td>
</tr>
</tbody>
</table>

---

Posters will be displayed on Monday - Wednesday in the Exhibition Hall, Auditorium 1. Odd-numbered posters will be attended on Monday 7 November and even-numbered posters on Tuesday 8 November during lunch time 13:00-14:15

---

www.endocrinology.org/events Society for Endocrinology BES 2016
EP17  “Please don’t operate on this patient” – a case of adrenaline running high
Irfan Khan, Paisal Hasan & Kathryn Lonnen

EP18  Bilateral adrenal nodules and pheochromocytoma associated with neurofibromatosis
Zeenat Banu & Ravi Menon

EP19  Challenging hypercalcaemia
Rahat Tauni & Nida Ali

EP20  Adult presentation of hypophosphatasia due to a novel compound heterozygous tissue nonspecific alkaline phosphatase (ALPL) mutation
Cathrina Farrell, Judith Strachan, Sripada Sankar, Catherine McWilliam, Faz Alipour, Paul Newey & Chris Schofield

EP21  Severe hypercalcaemia following Vitamin D replacement therapy in patient found to have co-existing sarcoidosis and primary hyperparathyroidism
Jodie Sabin, Jack Scannell, Jane Donald & Alison Evans

EP22  Albright hereditary osteodystrophy
Tobias Cox, Rajni Mahto, Umar Raja & Rakhi Kakad

EP23  Idiopathic infantile hypercalcaemia (IHH) caused by a missense mutation of 125-dihydroxyvitamin D2 24-hydroxylase (CYP24A1)
Victoria Stokes, Caroline Gorvin, Bahram Jafar-Mohammadi, Fiona Ryan & Rajesh Thakker

EP24  An unusual case of hypercalcaemia
Grace Pink, Ramanand Athavale, Shatrughan Sah & Rajni Mahto

EP25  Association of neurofibromatosis type 1 with primary hyperparathyroidism: report of a case
Emily Austin & Andrew Bates

EP26  Osteocalcin suppression may be a useful marker of steroid exposure
Yvette Ang, Adam Leckey, Sirazum Choudhury, Alan Courtney, Tricia Tan & Karim Meenan

EP27  Maternal hypercalcaemia due to CYP24A1 loss of function mutations
Thomas Upton, Chris Florkowski, Ian Phillips & Penny Hunt

EP28  Lithium associated hyperparathyroidism (LAH): Cinacalcet is an effective alternative treatment option
Satya V Sagi, Neelima Jampana, Jeyanthi Rajkann & Samson Oyibo

EP29  Severe hypercalcaemia in sarcoidosis: is Vitamin D replacement safe?
Ahmed El-Laboudi, Rozana Raml & Emma Hatfield

EP30  Hypercalcaemia-induced psychosis due to primary hyperparathyroidism in pregnancy
Alice Thomas, Kirun Gunganah, Girish Rayanagoudar, Elliot Williams, Philippa Hanson, Williams Drake, Daniel Berney, Laila Parvanta, Simon Kirwin & Karl Metcalfe

EP31  Hypercalcaemia due to pelvic sarcoidosis
Julia Burkert, Jane Evans & Nicola Neary

EP32  Normocalcemic tetany after parathyroidectomy for hyperparathyroidism
Umaira Aziz, Ritwikka Mallik, Swarupini Ponnampalam & Ali Rathore

EP33  Can parathyroid carcinoma be preoperatively predicted?
Adnan Agha, Kerrie Anne Aldridge & Sofia Salahuddin

EP34  A pain in the neck (or is it in the neck?)
Rodica Chelmenciu & Raj Tanday

EP35  An interesting case of ‘skyrocketing hypercalcaemia’
Irfan Khan, Jawad Bashir & Fong Chau

EP36  Periodic episodes of weakness over 7 years
Jolyon Dales, Pradeep Vasudevan & Marie-France Kong

EP37  Spurious hypoglycaemia caused by an IgM paraprotein
Annie Armstrong, Nadia Zarif & Daryl Meeking

EP38  Hypokalaemic periodic paralysis
Vikram Aarella, Anjan Lenkalapally, Ramya Parasa, Mahesh Cheryala & Bhavani Merugu

EP39  A young person with recurrent severe hypokalaemia – familial, iatrogenic or just unknown?
Muhammad Shaqfat, Navya Basavaraju, Srinivasa Rangan, Prashant Singh & Probab Moulik

EP40  Insulinoma misdiagnosed as alcohol-induced hypoglycaemia
Khaled Tofeq, Michelle Howarth & Prasanna Rao-Balakrishna

EP41  A rare case of diabetic ketoacidosis (DKA) in a patient with genetically confirmed maturity onset diabetes of young (MODY)
Hannah McQuade, Sajjad Ahmad & Stanaway Stephen

EP42  Birds of a feather flock together: maternally inherited diabetes and deafness Medicare mitochondrial encephalopathy lactic acidosis and stroke-like episodes
Adnan Agha, Yusuf Ansari, Hammad Bajwa & Jonathan Webber

EP43  Navigating troubled waters: hyperglycaemic hyperosmolar state precipitated by nephrogenic diabetes insipidus
Panizad Avari, Aditi Sharma, Suhanjya Samarasinge & Qurinns Barnor

EP44  A case of reversible elevation in liver enzymes in a patient with poorly controlled type 1 diabetes
Nneka Obisi, Adam Al-Hakim, Hassan Kahal & Belinda Allan

EP45  An unusual cause of hypoglycaemia
Steven Law, Triona O’shea, Penelope Hyatt, Anukul Garg & Chidambaram Nethaji

EP46  Management of thyrotoxicosis with chronic neutropenia, case report
Nida Pasha, Kathryn Hodson, M Vidarthi, Nemanja Stojanovic & Frederick Nkonge

EP47  Hyperosmolar hyperglycaemic state following diazoxide therapy for insulinoma
Arshiya Tabasum, Peter Taylor, Thomas Dacruz, Katherine Kang, Mina Wenke-Briggs, Katie Jenkins & Hemanth Bolusani

EP48  Resistant hypertension – a fourth cause? Katherine Powell & Khin Swe Myint

EP49  A case of euglycaemic diabetic ketoacidosis in a patient treated with canagliflozin
Katherine Hodson, Nida Pasha, Ede Casey, Gangani Yakandawala & Nemanja Stojanovic

EP50  Acute disseminated encephalomyelitis (ADEM) secondary to severe diabetic ketoacidosis
Anne DeBray, Karthik Munichoodappa, Amar Puttanna & Parijat De

EP51  Spontaneous hypoglycaemia in a non-diabetic man with end stage renal disease caused by repaglinide or endogenous hyperinsulinemia: an enigma entangled
Rahat Ali Tauni, Shiu-Ching Soo & Ritwik Banerjee

Posters will be displayed on Monday – Wednesday in the Exhibition Hall, Auditorium 1.
Odd-numbered posters will be attended on Monday 7 November and even-numbered posters on Tuesday 8 November during lunch time 13:00–14:15
EP108 Transient thyrotoxicosis following external beam radiotherapy to the neck Ritwik Mallik, Swarupini Ponnampalam & James Ahlquist

EP109 The night when a floppy Chinese lad almost died due to his thyroid Jawad Bashir, David Price, Irfan Khan & Tamar Saeed

EP110 A case of undetectable thyroid hormones Samantha Hayes, Lucy Hawkins, David Halsall & Supriya Joshi


EP112 A lady with psycho-affective symptoms due to Hashimoto’s encephalopathy Jawad Bashir, David Price, Irfan Khan & Tamar Saeed

EP113 A big price for a little mistake: similar presentations but diverse management of thyroid storm. Use of extracorporeal membrane oxygenation (ECMO) in hyperthyroidism related cardiomyopathy Mawara Iftikhar & Anna Crown

EP114 Thymic hyperplasia in Graves’ disease – case presentation and review of current literature Alex Lewis & Kelly Cheer

EP115 Could a stitch in time save nine? Rodica Chelmenciuc, Grace Cooper & Raj Tanday

EP116 Can myxedema coma be managed in a ward? A complicated case of myxedema with peg feeding Fareha Najeeb Mohideen Bawa & Yahya Mahgoub’
MONDAY 7 NOVEMBER

Industry-sponsored Satellite Symposium
13.15–14:15
SYNDICATE 1

**SHIRE SATELLITE: OPTIMISING THERAPY: A PATIENT-CENTRED APPROACH TO THE TREATMENT OF ADRENAL INSUFFICIENCY**

- **Chair:** Robert Murray (Leeds)
- A Shire sponsored satellite symposium
- Adrenal insufficiency: Benefits of a patient-centred approach
  Robert Murray (Leeds)
- Patient education, treatment concerns and non-adherence: the need for change in adrenal insufficiency
  Sofia Llahana (London)
- Glucocorticoid replacement therapy: challenges, controversies, and strategies
  Deirdre Maguire (Harrogate)

Industry-sponsored Satellite Symposium
13.15–14:15
SYNDICATE 3

**BESINS SATELLITE: THE TESTOSTERONE DEBATES 2016**

- **Chair:** Francesca Swords
- A Besins sponsored satellite symposium
- Is testosterone good or bad for the heart?
  For the motion that testosterone is good for the heart
  Hugh Jones (Barnsley)
  Against the motion that testosterone is good for the heart
  Channa Jayasena (London)
- All symptomatic men with serum T<10nmol/l should receive replacement therapy
  For the motion
  Adrian Heald (Crewe)
  Against the motion
  Pierre Bouloux (London)

TUESDAY 8 NOVEMBER

Industry-sponsored Satellite Symposium
13.00–14:00
SYNDICATE 1

**PFIZER SATELLITE: ADOLESCENTS & YOUNG ADULTS: MORE THAN JUST HORMONES!**

- **Chair:** Helen Simpson (Cambridge)
- A Pfizer Ltd sponsored satellite symposium
- What young people tell us?
  Helena Gleeson (Birmingham)
- Filling the Training Gap
  Kelly Cheer (Manchester)
- National Audit of Transition in Endocrinology meets NICE guidance
  Paul Dimitri (Sheffield)
- Panel discussion
  All

Industry-sponsored Satellite Symposium
13.30–14:30
SYNDICATE 3

**IPSEN SATELLITE: PERSONALISED MANAGEMENT OF ACROMEGALY**

- **Chair:** Mark Gurnell (Cambridge)
- An Ipsen sponsored satellite symposium
- Biochemical control – which targets should we be aiming for?
  Aled Rees (Cardiff)
- Comorbidities – it’s not just about the numbers
  Miles Levy (Leicester)
- Met-PET/MRI guided management – which patients should we refer?
  Mark Gurnell (Cambridge)
OPENING TIMES
An exhibition of related products, services and technologies is being held in the Exhibition Hall throughout the conference. This provides delegates with an excellent opportunity to interact with industry and to familiarise themselves with the latest advances in technology and therapeutics.

Please note that the exhibition opening times are as follows:

- Monday 7 November 09:00 – 21:00
- Tuesday 8 November 09:30 – 16:45
- Wednesday 9 November 09:30 – 15:00 (no access to the exhibition hall after 15:00)

The companies listed on the following pages will be exhibiting their products during the conference and welcome you to their stand. Please see the opposite page for the floor plan.

PLAN KEY

<table>
<thead>
<tr>
<th>STAND(S)</th>
<th>EXHIBITOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>A10/1</td>
<td>Addison’s Disease Self Help Group</td>
</tr>
<tr>
<td>A10/2</td>
<td>Hypopara UK</td>
</tr>
<tr>
<td>A20/1</td>
<td>CAH Support Group</td>
</tr>
<tr>
<td>A20/2</td>
<td>dsdfamilies</td>
</tr>
<tr>
<td>A30/1</td>
<td>Turner Syndrome Support Society</td>
</tr>
<tr>
<td>A30/2</td>
<td>The Klinefelter’s Syndrome Association</td>
</tr>
<tr>
<td>A40/1</td>
<td>The Association for Multiple Endocrine Neoplasia Disorders (AMEND)</td>
</tr>
<tr>
<td>A40/2</td>
<td>ACC Support UK</td>
</tr>
<tr>
<td>A50/1</td>
<td>The Pituitary Foundation</td>
</tr>
<tr>
<td>A50/2</td>
<td>British Thyroid Foundation</td>
</tr>
<tr>
<td>A60/2</td>
<td>ALD Life</td>
</tr>
<tr>
<td>B10</td>
<td>Novartis/Sandoz</td>
</tr>
<tr>
<td>B20</td>
<td>Internis Pharmaceuticals Ltd</td>
</tr>
<tr>
<td>B30</td>
<td>Strongbridge Biopharma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STAND(S)</th>
<th>EXHIBITOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>B40</td>
<td>Besins Healthcare</td>
</tr>
<tr>
<td>B50/B60</td>
<td>HRA Pharma</td>
</tr>
<tr>
<td>B70</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>C10</td>
<td>Kyowa Kirin International PLC</td>
</tr>
<tr>
<td>C20</td>
<td>Alexion</td>
</tr>
<tr>
<td>C30</td>
<td>Ferring</td>
</tr>
<tr>
<td>C40</td>
<td>Literature and Information</td>
</tr>
<tr>
<td>C50</td>
<td>Ipsen</td>
</tr>
<tr>
<td>C60</td>
<td>International Society of Endocrinology</td>
</tr>
<tr>
<td>D10</td>
<td>Lilly</td>
</tr>
<tr>
<td>D20</td>
<td>Merck</td>
</tr>
<tr>
<td>D30</td>
<td>Imaging Equipment Limited</td>
</tr>
<tr>
<td>D40/D50</td>
<td>Bioscientifica</td>
</tr>
<tr>
<td>D60/D70</td>
<td>Society for Endocrinology</td>
</tr>
<tr>
<td>E20</td>
<td>Shire</td>
</tr>
<tr>
<td>E30</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>
notably young boys: those with the gene show no initial problems and thrive alongside peers, until symptoms show. Those males that reach adulthood will develop AMN, a lesser phenotype of ALD causing mild to severe mobility issues: of these 30% will develop terminal cerebral ALD. The majority of males initially develop primary idiopathic adrenal insufficiency, a key indicator for ALD.

ALD and AMN cause far reaching consequences and families/carers have to manage a range of difficulties including sudden loss of ability (sight, speech, movement, swallowing), bereavement, harrowing medical treatments, emotional trauma, acquired disability, job loss and home adaptations.

Although there is no treatment to stop AMN developing, terminal cerebral ALD can be prevented with bone marrow transplant provided a patient has been diagnosed correctly and monitored regularly. Once symptoms become apparent this treatment is not viable.

A key objective for ALD Life is to ensure all relevant adrenal insufficiency diagnoses are checked for ALD, particularly in adult males.

www.aldlife.org

**ADDISON’S DISEASE SELF HELP GROUP**

Stand A10/1

Addison’s is a rare, endocrine condition where the adrenal glands cease to produce certain hormones essential for life. Continuous, daily treatment with replacement steroid hormones is required and medication must be taken several times a day at carefully timed intervals. With the right balance of daily medication, and good medical support, most people can lead long and active lives. However, they are also likely to need emergency medical treatment to prevent a near-death adrenal crisis at some stage.

First founded in 1984 The Addison’s Disease Self-Help Group is a registered charity: no. 1106791. We work to support people with adrenal failure and their families and to raise medical awareness of this rare, endocrine condition. The group publishes a quarterly newsletter, runs an electronic discussion group, holds an annual medical lecture, regional seminars and social meetings.

A range of patient education materials are available on the website:

www.addisons.org.uk

**ALD LIFE**

Stand A60/2

ALD Life provides practical, emotional and financial support for patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN), their families and carers. We work collaboratively with researchers and medical professionals to develop and ensure best practice in the treatment and care of patients with ALD and AMN.

ALD is an often misdiagnosed, rare, terminal, X-linked genetic, metabolic disorder caused by a faulty/missing ABCD1 gene. ALD is not a disease of developmental delay and affects males of all ages, most notably young boys: those with the gene show no initial problems and thrive alongside peers, until symptoms show. Those males that reach adulthood will develop AMN, a lesser phenotype of ALD causing mild to severe mobility issues: of these 30% will develop terminal cerebral ALD. The majority of males initially develop primary idiopathic adrenal insufficiency, a key indicator for ALD.

ALD and AMN cause far reaching consequences and families/carers have to manage a range of difficulties including sudden loss of ability (sight, speech, movement, swallowing), bereavement, harrowing medical treatments, emotional trauma, acquired disability, job loss and home adaptations.

Although there is no treatment to stop AMN developing, terminal cerebral ALD can be prevented with bone marrow transplant provided a patient has been diagnosed correctly and monitored regularly. Once symptoms become apparent this treatment is not viable.

A key objective for ALD Life is to ensure all relevant adrenal insufficiency diagnoses are checked for ALD, particularly in adult males.

www.aldlife.org

**ASSOCIATION OF MULTIPLE ENDOCRINE NEOPLASIA DISORDERS (AMEND)**

Stand A40/1

A UK-registered charity since 2003, AMEND provides information and support services to families affected by the rare genetic cancer syndromes, multiple endocrine neoplasia (MEN). MEN disorders predispose sufferers to developing tumours or cancers in more than one gland of the body. Children of affected parents have a 50% chance of inheriting the condition. AMEND provides free email and telephone support including psychological counselling, runs

www.amend.org.uk

**ALEXION**

Stand C20

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people’s lives depend on our work.

www.alexion.com

**ACC SUPPORT UK**

Stand A40/2

ACC Support UK is a joint venture between AMEND and the NET Patient Foundation which aims to provide information resources and support services to all those affected by adrenocortical cancer. Free resources are developed with help from expert medical advisors. ACC Support UK’s free 2016 patient event is to be held in association with the ENS@T meeting on Saturday 26 November in Birmingham.

www.accsupport.org.uk
information events, produces information resources for adults and children, and awards grants for research into the conditions. Further information on can be found on our HONCode certified website at www.amend.org.uk

**BIOSCIENTIFICA**

Stand D40/D50

Bioscientifica collaborates with learned societies worldwide to provide high-quality publishing, association management and events services to the biomedical community. Bioscientifica publishes the Society’s official journals: *Journal of Endocrinology*, *Journal of Molecular Endocrinology*, *Endocrine-Related Cancer*, *Endocrine Connections* and *Endocrinology, Diabetes & Metabolism Case Reports*, among other titles. Visit our stand to: Find out about how the SfE journals directly facilitate the work of the Society. Learn about exclusive publishing discounts for SfE members. Play our ‘Matching Pairs’ game to be in with a chance of winning an endocrine plushie!

**BESINS HEALTHCARE**

Stand B40

Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.

Over the last 30 years, Besins has established a strong and reputable name in the production of drugs for the treatment of gynaecological, fertility and obstetrical conditions as well as androgen deficiency and has become a renowned player in the area of hormonal therapies.

Besins global commercial operations is based in the UK and our drugs are distributed in more than 90 countries via subsidiary companies (Besins affiliates) as well as a network of business partners. Besins is actively pursuing new growth opportunities through acquisition and expansion into new territories, bringing significant growth over the coming years.

Besins products are manufactured in a number of countries including France, Belgium and Spain.

To ensure we meet the needs of tomorrow, Besins has two primary research and development facilities across the globe. One of our research facilities is Laboratories Besins International, located in France, the other is BHR Pharma, USA, which is an affiliate of Ascend Therapeutics, Inc. www.besins-healthcare.com

www.besins-healthcare.com

**BRITISH THYROID FOUNDATION**

Stand A50/2

The British Thyroid Foundation is 25 years old this year and has been providing support, information and research funding since its launch at the SfE BES meeting in Harrogate in 1992. Our 2017 Research Award provides funding of £20,000 and the value of our two Nurse Awards is £500/£1000. Visit our stand to find out more about our work and current campaigns.

www.btf-thyroid.org

**THE CAH SUPPORT GROUP**

Stand A20/1

The CAH Support Group was set up to help families affected by CAH approximately 20 years ago. It is a sub group of CLIMB (Children Living with Inherited MetaBolic diseases), registered charity no: 1089588.

Our aims are:

a) To give support to those with CAH and their families

b) To increase awareness of the condition to the public and to the medical profession

c) To raise funds to support research.

We hold conferences at regular intervals and a newsletter is sent out 3 times a year. Our key to success is getting information to where it is required as soon as possible after the need is recognised; i.e. at diagnosis.

www.livingwithcah.com

**EXHIBITION**

Find out about our Practical Publishing Advice Workshop delivered by Editorial Board members and journal representatives. Pick up a cover art postcard with information about our cover art competition, view our cover art gallery and create your own fun journal cover souvenir. Bioscientifica is owned by the Society for Endocrinology, and invests all profits in partner societies to help advance biomedical education, research and practice ... profit for good.

Bioscientifica, 22 Apex Court, Woodlands
Bradley Stoke, Bristol, BS32 4JT, UK

www.bioscientifica.com

Bioscientifica, 22 Apex Court, Woodlands
Bradley Stoke, Bristol, BS32 4JT, UK

www.bioscientifica.com

www.endocrinology.org/events
**DSD FAMILIES**

**Stand A20/2**

dsdfamilies is a resource for those who want to know more about differences/disorders of sex development (DSD). DSD is a large family of conditions which affect kids in many different ways, and often involve the development of the reproductive organs and genitals.

Our main objective is to help families understand their child’s condition, supporting them to raise their children to become confident and happy young people. dsdfamilies, encompassing dsdteens.org, is now transforming into a charity and is looking to further develop its portfolio of work in consultation with children, young people, families and healthcare professionals.

[www.dsdfamilies.org](http://www.dsdfamilies.org) | [www.dsdteens.org](http://www.dsdteens.org) | info@dsdfamilies.org

---

**FERRING**

**Stand C30**

Ferring Pharmaceuticals is a multi-national company with corporate headquarters in Saint-Prex Switzerland. The organisation’s marketing, medical services and sales teams operate in more than 50 countries and employ over 4000 people throughout the world.

Ferring’s portfolio demonstrates an exceptionally innovative and successful track record in endocrinology, reproductive health - infertility and obstetrics, urology, gastroenterology, oncology and men’s health.

Ferring is a world leader in the research and development of peptides and hormone therapies, focusing on producing treatments that enable doctors to treat patients on the body’s own terms.

Ferring Pharmaceuticals Ltd, Drayton Hall, Church Road, West Drayton UB7 7PS (Tel: 0208 580 4100, Fax: 0844 9310057)

[www.ferring.co.uk](http://www.ferring.co.uk)

---

**HRA PHARMA**

**Stand B50/B60**

HRA Pharma has been a significant presence in the niche area of Adrenal Cortical Carcinoma since 2004, providing a standard therapy for this serious condition and a free of charge drug monitoring service to support clinician in optimising its use.

HRA Pharma has more recently become a significant player in the field of Cushing’s Syndrome investing in two well established but key
treatment entities to further enhance its standing in the endocrine arena.

HRA Pharma is currently investing in research for this disorder with a view to expanding the current knowledge base and optimising patient management.

[www.hra-pharma.com](http://www.hra-pharma.com)

---

**HYPOPARA UK**

**Stand A10/2**

Hypopara UK is the national patient organisation dedicated to supporting people with all parathyroid conditions and to improving the diagnosis, prevention and treatment of all forms of hypoparathyroidism and hyperparathyroidism.

We offer support and information to empower patients and their families to become involved and active in the management of their condition through our website, leaflets, online forums and telephone helplines. To increase a global awareness of hypopara we have established a World Hypopara Awareness Day (June 1st); we work closely with organisations around the world and have founded new ones. This year, we have met with European hypopara groups in London to discuss a European Hypopara Alliance.

We have contributed to the BTA guideline for the ‘Management of Thyroid Cancer’ guidelines 2014 and the ESE guideline on the ‘Treatment Chronic Hypoparathyroidism’ 2015. We are working with BAETS to produce patient information. We work closely with our fantastic Clinical Advisory Team in the UK, a nationwide group of renowned endocrinologists with a particular interest in calcium homeostasis and bone metabolism, to raise awareness, develop new protocols and advance research into more effective treatment.

[www.hypopara.org.uk](http://www.hypopara.org.uk)

---

**IMAGING EQUIPMENT LIMITED (IEL)**

**Stand D30**

Imaging Equipment Limited (IEL) is extremely proud to be representing such global market leaders in the Nuclear Medicine arena as; Advanced Accelerator Applications (AAA)*, Cyclomedica, Eckert and Ziegler, ROTOP and Tema Sinergie, thus being able to accurately match customers’ requirements and build packages that meet both their technical specifications and budgetary demands. IEL’s team of specialist Nuclear Medicine sales consultants, supported by a dedicated and experienced technical team, provide a personal and
high-quality customer service across the UK and Ireland.

*Imaging Equipment Limited is owned by Advanced Accelerator Applications PLC (AAA) of Geneva, Switzerland NASDAQ: AAAP.

www.imagingequipment.co.uk

INTERNATIONAL SOCIETY OF ENDOCRINOLOGY
Stand C60

Since its foundation in 1960, the International Society of Endocrinology (ISE) has pursued the worldwide advancement of education, science and patient care in Endocrinology.

Today the society forms a strategic federation of National Endocrine Societies which aims to stimulate international cooperation and coordinate scientific exchange, debate and dissemination between healthcare professionals around the world.

ISE’s current membership comprises over 70 national endocrinology societies, representing nearly 50,000 endocrinologists worldwide.

The flagship of the ISE remains its International Congress (http://isendo.org/events.html), held in rotation every two years in partnership with one of its National Societies across The Americas, Europe/Africa and Asia/Oceania.

http://isendo.org

INTERNIS
Stand B20

Founded in 2010, Internis is a UK speciality pharmaceutical company engaged in the development and commercialisation of highly effective and innovative new medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency.

www.internisvitd3.com

IPSEN
Stand C50

Ipsen is committed to endocrine disorders with therapies to treat pituitary diseases (acromegaly), growth disorders (growth hormone and IGF-1 deficiencies) or other endocrine diseases (such as precocious puberty). Our ambition is to become a recognized and unique partner in patient program management and provide innovative resources. Many patients living with acromegaly experience substantial pain and discomfort, which affects sleep, family life, and their ability to work. Early diagnosis, effective treatment and frequent monitoring are critical for improving clinical symptoms and outcomes of the disease. Ipsen continues to work on solutions that will improve the quality of life of patients living with acromegaly. The Group is currently developing extended-release formulations of Somatuline that would enable patients to have fewer injections. As part of its mission to be a global advocate for patients affected by rare endocrine disorders, Ipsen is engaged with patient groups, key scientific leaders, medical societies and institutions to develop educational projects and initiatives that help physicians manage the treatment of these conditions worldwide. The Group is also involved in supporting the development of networks of experts to promote international dialog between specialists, including several initiatives with the European Society of Endocrinology.

www.ipsen.co.uk

KLINFELETER’S SYNDROME ASSOCIATION (KSA)
Stand A30/2

The Klinefelter’s Syndrome Association (KSA) works to raise awareness of XXY/KS amongst GPs and society generally.

The KSA is run entirely by volunteers with members from across the world! It supports all affected by XXY/KS – including family, friends, employers. It is concerned that there are few but conflicting reports regarding the effect of testosterone on osteoporosis, fatigue and lack of muscle in XXY/KS adults. Gender issues are rarely considered.

The KSA hosts an annual conference, Facebook pages and an excellent website: ksa-uk.net. It runs Activity Weekends and Members’ Meetings.

Free membership for health professionals is available at the KSA stand at SfE BES 2016, contact chair@ksa-uk.net or visit our website www.ksa-uk.net

KYOWA KIRIN LIMITED
Stand C10

Kyowa Kirin Limited is a specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. Headquartered in Galashiels, Scotland, it is a subsidiary of Kyowa Hakko Kirin Co., Ltd., the Japan-based global

www.endocrinology.org/events
broadly available novel therapies that help to improve and extend the lives of patients living with cancer and blood disorders.

Supporting oncology healthcare professionals starts with understanding that cancer and blood disorders are a complex group of diseases fuelled by many underlying mechanisms. Research and development (R&D) at Novartis utilises recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies. To support these efforts, the company makes considerable investments in technologies and expertise both internally and externally.

Novartis is committed to providing patients with access to its therapies. Providing access to cancer treatments is complex, demanding collaboration with industry, government, national health services, insurers, physicians and patient groups. Novartis works with these groups around the world to find innovative means to enhance access.

www.novartis.com

Sandoz Biopharmaceuticals is a Novartis company and a pioneer in the development of Biosimilar therapeutics, with a vision to dramatically increase worldwide patient access to essential high-quality biopharmaceutical products.

Sandoz was the first company to have a biosimilar approved through the stringent EU regulatory pathway, closely followed by two more biosimilars. By incorporating quality by design with state of the art technology, Sandoz Biopharmaceuticals is committed to helping make quality healthcare affordable for more patients and to slow the increase in escalating global healthcare costs.

www.sandoz.com

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries. For more information, visit www.novonordisk.co.uk.
The society for Endocrinology serves as a world-leading voice of endocrinology representing a global community of scientists, clinicians and nurses who work with hormones. Together we work to improve public health by advancing and leading the way in endocrine education and research, and engaging wider audiences with the science of hormones. Come and visit us at the stand (D60/D70) where you can find out more about joining as a member, renew your membership, change your Endocrine Network preferences and get information on the grants, events and funding opportunities available to you as a member.

www.endocrinology.org

**STRONGBRIDGE BIOPHARMA**

**Stand B30**

Strongbridge Biopharma is a biopharmaceutical company focused on bridging treatment gaps in rare diseases, initially in endocrine disorders. COR-003 is the lead product candidate, being evaluated for endogenous Cushing’s syndrome in the SONICS trial.

www.strongbridgebio.com

**THE PITUITARY FOUNDATION**

**Stand A50/1**

The Pituitary Foundation is a national charity working in the United Kingdom and Republic of Ireland, supporting pituitary patients, their families and friends.

Our aims are to offer support through the pituitary journey, provide information to the community, and act as the patient voice to raise awareness and improve services

www.pituitary.org.uk

**SHIRE**

**Stand E20**

Shire enables people with life altering-conditions to lead better lives. We focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine.

www.shirepharmaceuticals.co.uk

The Society for Endocrinology has agreed a new two-year partnership with Pfizer. The agreement is first of its kind for the Society, and aims to deliver maximum benefit to both organisations and the broader aim of advancing endocrinology.

www.pfizer.co.uk

The Pituitary Foundation is a national charity working in the United Kingdom and Republic of Ireland, supporting pituitary patients, their families and friends.

Our aims are to offer support through the pituitary journey, provide information to the community, and act as the patient voice to raise awareness and improve services

www.pituitary.org.uk

**SOCIETY FOR ENDOCRINOLOGY**

**Stand D60/D70**

The Society for Endocrinology serves as a world-leading voice of endocrinology representing a global community of scientists, clinicians and nurses who work with hormones. Together we work to improve public health by advancing and leading the way in endocrine education and research, and engaging wider audiences with the science of hormones. Come and visit us at the stand (D60/D70) where you can find out more about joining as a member, renew your membership, change your Endocrine Network preferences and get information on the grants, events and funding opportunities available to you as a member.

www.endocrinology.org

**STRONGBRIDGE BIOPHARMA**

**Stand B30**

Strongbridge Biopharma is a biopharmaceutical company focused on bridging treatment gaps in rare diseases, initially in endocrine disorders. COR-003 is the lead product candidate, being evaluated for endogenous Cushing’s syndrome in the SONICS trial.

www.strongbridgebio.com

**TURNER SYNDROME SUPPORT SOCIETY (TSSS)**

**Stand A30/1**

The TSSS aims to offer support, social contact and information on all aspects of Turner syndrome to girls and women with TS and their families. The Society also works closely with health professionals involved in the care of those with TS especially members of the Society of Endocrinology.

Please visit the TSSS stand at any time during the conference to collect the wide range of information the Society has to offer.

www.tss.org.uk

Shire enables people with life altering-conditions to lead better lives. We focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine.

www.shirepharmaceuticals.co.uk
SOCIAL MEDIA

The Society for Endocrinology welcomes the use of social media at its conferences and events.

To ensure that the needs of all parties are met, we ask that delegates using social media comply with the following policy:

**Use of social media**

Delegates are encouraged to Tweet about the conference using the hashtag #SfEBES2016.

If you plan to blog from the conference, we respectfully ask you to inform us before the conference takes place at media@endocrinology.org.

We ask that all writers attending the conference gain approval from a speaker/poster presenter prior to quoting or publishing that individual’s scientific results on the internet or through other forms of media. This policy applies to both professional writers/journalists and to non-journalists blogging about the conference or otherwise sharing information among a group of individuals.

All speakers/poster presenters will be made aware of this policy and have the right to ask delegates not to disseminate their research online or through other forms of media. Delegates are asked to respect the wishes of speakers/presenters who make this request.

**PHOTOGRAPHY**

Please refrain from taking photographs of any session/poster without the prior consent of the conference organisers and the speaker or poster presenter.

Any official photographs taken at the conference may be used by the organisers for promotional purposes. If you have any concerns or queries about this issue, please visit the registration desk or contact Bioscientifica on +44 (0)1454 642210 or conferences@endocrinology.org.

SOCIAL MEDIA AND PHOTOGRAPHY

PATIENT SUPPORT GROUPS

The Society for Endocrinology is pleased to be able to promote the following Patient Support groups, many of which have stands in the SfE BES 2016 Exhibition.

Addison’s Disease Self Help Group (Exhibiting)
www.addisons.org.uk

ACC Support UK (Exhibiting)
www.accsupport.org.uk

ALD Life (Exhibiting)
www.aldlife.org

Androgen Insensitivity Syndrome Support Group
www.aissg.org

Anorchidism Support Group
www.asg4u.org

Association for Multiple Endocrine Neoplasia Disorders (Exhibiting)
www.amend.org.uk

British Thyroid Foundation (Exhibiting)
www.btf-thyroid.org

Butterfly Thyroid Cancer Trust
www.butterfly.org.uk

CAH Support Group (Exhibiting)
www.livingwithcah.com

Child Growth Foundation
www.childgrowthfoundation.org

dsdfamilies (Exhibiting)
www.dsdfamilies.org

FIPA Patients
www.fipapatients.org

Gender Trust
www.gendertrust.org.uk

Hyppopara UK (Exhibiting)
www.hymphopara.org.uk

Kallmann Syndrome Organisation
www.kallmanns.org

Klinefelter Organisation
www.klinefelter.org.uk

Klinefelter’s Syndrome Association UK (Exhibiting)
www.ksa-uk.net

National Association For Premenstrual Syndrome
www.pms.org.uk

Net patient Foundation
www.netpatientfoundation.com

Paget’s Association
www.paget.org.uk

Pituitary Foundation (Exhibiting)
www.pituitary.org.uk

Prader-Willi Syndrome Association
www.pwsa.co.uk

Sexual Advice Association
www.sda.uk.net

Thyroid Eye Disease Charitable Trust
www.tedct.co.uk

Turner Syndrome Support Society (Exhibiting)
www.tss.org.uk

Verity (PCOS)
www.verity-pcos.org.uk
ENVIRONMENTAL POLICY

At the Society for Endocrinology we are committed to ‘going green’ and providing a first-class conference in such a way that we minimise any negative impact on the environment.

Great care has been taken to consider the sustainability issues associated with the conference. Please help us to continue this green initiative by:

- walking and using public transport during your stay in Brighton
- offsetting your travel-related carbon impact (for a list of carbon offset providers, we suggest you visit www.carboncatalog.org).

The Brighton Centre is committed to reducing the environmental impact of events and making a positive contribution to people’s lives and the local economy. The centre’s Sustainable Events Programme has achieved two world class International Standards for Environmental Management (ISO 14001) and Sustainable Events (ISO 20121).
Looking for the latest publications in endocrinology?

Please go to [www.karger.com/endocrinology](http://www.karger.com/endocrinology) and profit from a **35% discount** on the following publications:

**Neuroendocrine Tumors**  
A Multidisciplinary Approach  
Editors: **M. Papotti** (Turin); **W.W. de Herder** (Rotterdam)  
X + 270 p., 51 fig., 26 in color, 27 tab., hard cover, 2015  
**Special price:**  
CHF 140.00 / EUR 131.00 / USD 165.00  

**Imaging in Endocrine Disorders**  
Editors: **M. Buchfelder** (Erlangen); **F. Guaraldi** (Turin)  
VIII + 156 p., 33 fig., 5 in color, 9 tab., hard cover, 2016  
**Special price:**  
CHF 117.00 / EUR 109.00 / USD 138.00  

**Cortisol Excess and Insufficiency**  
Editors: **E. Arvat** (Turin); **A. Falorni** (Perugia)  
VIII + 216 p., 17 fig., 4 in color, 20 tab., hard cover, 2016  
**Special price:**  
CHF 127.00 / EUR 119.00 / USD 150.00  

**Sports Endocrinology**  
Editors: **F. Lanfranco** (Turin); **C. Strasburger** (Berlin)  
VIII + 172 p., 13 fig., 5 in color, 13 tab., hard cover, 2016  
**Special price:**  
CHF 104.00 / EUR 98.00 / USD 122.00  

Use the promotional code **SFE16** to profit from this special offer.

Prices subject to change, VAT not included  
EUR price for eurozone countries, USD price for USA and Latin America only
### Scientific programme

**MONDAY**
- **07.00**: Registration
- **08.00**: Breakfast
- **09.00**: Plenary Session 1
- **10.00**: Symposium 2
- **11.00**: Symposium 3
- **12.00**: Symposium 4
- **13.00**: Lunch & Poster Viewing
- **14.00**: Symposium 5
- **15.00**: Symposium 6
- **16.00**: Symposium 7
- **17.00**: Symposium 8
- **18.00**: Symposium 9
- **19.00**: Symposium 10
- **20.00**: Welcome Reception

**TUESDAY**
- **07.00**: Registration
- **08.00**: Breakfast
- **09.00**: Plenary Session 2
- **10.00**: Symposium 11
- **11.00**: Symposium 12
- **12.00**: Symposium 13
- **13.00**: Lunch & Poster Viewing
- **14.00**: Symposium 14
- **15.00**: Symposium 15
- **16.00**: Symposium 16
- **17.00**: Symposium 17
- **18.00**: Symposium 18
- **19.00**: Symposium 19
- **20.00**: Conference Dinner

**WEDNESDAY**
- **07.00**: Registration
- **08.00**: Breakfast
- **09.00**: Plenary Session 3
- **10.00**: Symposium 20
- **11.00**: Symposium 21
- **12.00**: Symposium 22
- **13.00**: Lunch & Poster Viewing
- **14.00**: Symposium 23
- **15.00**: Symposium 24
- **16.00**: Symposium 25
- **17.00**: Symposium 26
- **18.00**: Symposium 27
- **19.00**: Symposium 28
- **20.00**: Closing Remarks

**Venue Key**
- **A1**: Exhibition Hall, Auditorium 1
- **A2**: Auditorium 2
- **S1**: Syndicate 1
- **S3**: Syndicate 3
- **S4**: Syndicate 4
- **TR**: The Restaurant (Third Floor)

**Session Type Key**
- Workshop
- Symposium
- Oral Communications
- Meet the Expert
- Satellite session
- Award winners
- Nurses session
- Futures
- Skills
- Tea & coffee
- Breakfast / Lunch